fluorouracil has been researched along with Blood Diseases in 163 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to examine the efficacy of a combination treatment of sequential irinotecan and doxifluridine, an intermediate of capecitabine, evaluated by the response rate and safety in patients with metastatic colorectal cancer." | 10.23 | A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer. ( Amano, M; Fukunaga, M; Ikeda, K; Ikeda, M; Ikenaga, M; Ishida, H; Kato, T; Mishima, H; Monden, M; Murata, K; Ohnishi, T; Ota, H; Sakamoto, J; Sekimoto, M; Tominaga, S, 2008) |
| "Adverse events associated with 5-fluorouracil (5FU) based adjuvant therapy in colorectal cancer (CRC) patients may predict survival." | 9.19 | Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity? ( André, T; Bono, P; de Gramont, A; Hermunen, K; Österlund, P; Poussa, T; Quinaux, E; Soveri, LM, 2014) |
| " This phase I/II trial was carried out to evaluate the combination of capecitabine and the proteasome inhibitor bortezomib in anthracycline and/or taxane-pretreated patients with metastatic breast cancer." | 9.13 | A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. ( Brossart, P; Freier, W; Greil, R; Kiewe, P; Kühnhardt, D; Kümmel, S; Lange, W; Lehenbauer-Dehm, S; Niederle, N; Possinger, K; Preiss, J; Regierer, A; Schippinger, W; Schmid, P; Van de Velde, H, 2008) |
| "The aim of this study was to evaluate the effects of a combination of folinic acid, 5-fluorouracil (5FU) and irinotecan (FOLFIRI 1) administered every 2 weeks in a population of elderly subjects with advanced colorectal cancer." | 9.13 | Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study. ( Badetti, JL; Berdah, JF; Chamorey, E; Codoul, JF; François, E; Hébert, C; Lesbats, G; Mari, V; Teissier, E, 2008) |
| "This study was conducted to determine, in patients with advanced-stage breast cancer, the maximum tolerated dose (MTD) of capecitabine administered orally for 7 days followed by a 7-day rest (7/7), a schedule based on a mathematical method for the optimization of anticancer drug scheduling." | 9.13 | Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. ( Dugan, U; Edwards, C; Feigin, K; Hudis, C; Norton, L; Patil, S; Tan, KL; Theodoulou, M; Traina, TA, 2008) |
| "The aim of the study was to analyse the toxicity and health related quality of life (HRQoL) of breast cancer patients treated with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) and TAC (docetaxel, doxorubicin, cyclophosphamide) with and without primary prophylactic G-CSF (PPG)." | 9.12 | Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony sti ( Adrover, E; Antón, A; Arcusa, A; Calvo, L; del Prado, PM; Fernandez-Chacón, C; Grosse, R; Iglesias, L; Isla, D; Lluch, A; López-Vega, JM; Martín, M; Mel, JR; Muñoz, M; Ramos, M; Rodríguez-Lescure, A; Roset, M; Ruiz, A; Seguí, MA; Zaluski, J, 2006) |
| "This phase II randomised trial compares oxaliplatin plus protracted infusion of 5-fluorouracil (pviFOX) or oxaliplatin plus capecitabine (XELOX) in the first-line treatment of advanced colorectal cancer (ACRC)." | 9.12 | Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial). ( Ballardini, P; Di Fabio, F; Gentile, AL; Giaquinta, S; Lelli, G; Martoni, AA; Mutri, V; Piana, E; Pinto, C; Rojas Llimpe, FL, 2006) |
| "This multicentre phase I/II study was designed to determine the maximum tolerated dose of irinotecan when combined with 5-fluorouracil and folinic acid according to the Mayo Clinic schedule and to evaluate the activity of this combination as first-line therapy in patients with advanced colorectal cancer." | 9.11 | Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. ( Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J, 2004) |
| "Combination therapy of irinotecan, folinic acid (FA) and 5-fluorouracil (5-FU) has been proven to be highly effective for the treatment of metastatic colorectal cancer." | 9.11 | Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. ( Adami, B; Galle, PR; Heike, M; Hohl, H; Höhler, T; Klein, O; Moehler, M; Schroeder, M; Siebler, J; Steinmann, S; Teufel, A; Zanke, C, 2004) |
| "The aim of this prospective study was to assess the efficacy, clinical benefit and safety of CPT-11 (irinotecan) in patients with stringently-defined 5-fluorouracil-resistant metastatic colorectal cancer (CRC)." | 9.09 | Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). ( Alexopoulos, CG; Blanc, C; Bleiberg, H; Blijham, GH; Cholet, P; Cote, C; Cunningham, D; Dirix, L; Fillet, G; Hérait, P; Levi, F; Panagos, G; Punt, CJ; Symann, M; Ten Bokkel Huinink, WW; Unger, C; Van Cutsem, E; Van Groeningen, C; Vannetzel, JM; Wils, J, 1999) |
| "This phase-II study was conducted to investigate the potential benefit from the addition of mitomycin to a conventional anthracycline-cisplatin- and 5-fluorouracil-based chemotherapy for recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type (UCNT)." | 9.09 | Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type. ( Alonso, S; Armand, JP; Chouaki, N; Cortès-Funes, H; Cvitkovic, E; Fandi, A; Hasbini, A; Lianes, P; Mahjoubi, R; Raymond, E; Taamma, A, 1999) |
| "To determine whether a combination chemotherapy regimen that contains epirubicin (fluorouracil, epirubicin, and cyclophosphamide [FEC]) is superior to the standard cyclophosphamide, methotrexate, and fluorouracil (CMF) combination in premenopausal women with axillary node-positive operable breast cancer." | 9.08 | Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collab ( Aapro, M; Amadori, D; Bliss, JM; Chilvers, CE; Coombes, G; Coombes, RC; Espié, M; Ferreira, EP; Gambrosier, P; Marty, M; McArdle, C; Morvan, F; Pérez-López, FR; Richards, M; Vassilopoulos, P; Villar-Grimalt, A; Wils, J; Woods, EM, 1996) |
| " 439 patients were entered into a phase III trial comparing a novel thymidylate synthase (TS) inhibitor Tomudex (raltitrexed, formerly ZD1694) with 5-FU and leucovorin (LV) for the treatment of advanced colorectal cancer." | 9.08 | Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group. ( Kerr, D; Palmer, M; Seymour, L; Zalcberg, J, 1998) |
| "32 consecutive early breast cancer patients were treated to evaluate the feasibility of an accelerated CEF regimen (cyclophosphamide 600 mg/m2, epirubicin 60 mg/m2 and 5-fluorouracil 600 mg/m2) given intravenously every 2 weeks for six cycles together with granulocyte colony stimulating factor, 5 micrograms/kg/day subcutaneously from day 4 to day 11." | 9.07 | A pilot study of accelerated cyclophosphamide, epirubicin and 5-fluorouracil plus granulocyte colony stimulating factor as adjuvant therapy in early breast cancer. ( Canavese, G; Catturich, A; Del Mastro, L; Garrone, O; Guenzi, M; Rosso, R; Sertoli, MR; Venturini, M, 1994) |
| "Twenty-two patients with previously untreated metastatic breast cancer and nineteen patients with refractory metastatic breast cancer were treated with trimetrexate (TMTX)." | 9.07 | Trimetrexate in untreated and previously treated patients with metastatic breast cancer: a Cancer and Leukemia Group B study. ( Carey, RW; Clamon, GH; Costanza, ME; Dawson, NA; Korzun, AH; Norton, L; Pollak, M; Vogelzang, NJ, 1991) |
| "The French Epirubicin Study Group carried out a randomized trial comparing epirubicin alone 75 mg/m2 with fluorouracil (5FU) 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 50 mg/m2 (FEC 50) and 5FU 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 75 mg/m2 (FEC 75) as first treatment for advanced breast cancer patients." | 9.07 | A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group. ( , 1991) |
| "Data on 162 women (90 premenopausal and 72 postmenopausal) with metastatic breast cancer randomized to receive cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF) on two Eastern Cooperative Oncology Group (ECOG) protocols were analyzed." | 9.05 | The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Carbone, PP; Cummings, FJ; Falkson, G; Falkson, HC; Gelman, RS; Tormey, DC, 1985) |
| "After mastectomy, 265 postmenopausal patients with node-positive breast cancer were stratified according to pathologic nodal status and estrogen-receptor (ER) status and randomized to receive either 12 cycles of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP), or CMFP plus tamoxifen (CMFPT), or observation alone." | 9.05 | Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study. ( Bennett, JM; Carbone, PP; Cummings, F; Falkson, G; Kalish, LA; Olson, JE; Taylor, SG; Tormey, DC, 1985) |
| ", Nutley, NJ) is an orally administered fluoropyrimidine carbamate that serves as a prodrug of 5-fluorouracil (5-FU), an integral component of chemotherapy (CT) regimens for metastatic colorectal cancer (mCRC)." | 8.86 | Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer. ( Boehm, KA; Cartwright, T; McCollum, D, 2010) |
| "Fluorouracil (5-FU) continuous infusion is superior to 5-FU bolus in patients with advanced colorectal cancer, but the survival difference between the two treatments is small and, therefore, the difference in toxicity profile is crucial in choosing a treatment for individual patients." | 8.80 | Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. ( Benedetti, J; Brufman, G; Buyse, M; Fryer, J; Hansen, R; Isacson, R; Laplanche, A; Leichman, C; Lévy, E; Lokich, J; Macdonald, J; Pater, J; Piedbois, P; Pignon, JP; Quinaux, E; Rougier, P; Ryan, L; Thirion, P; Weinerman, B; Zee, B, 1998) |
| "To assess the impact of single-nucleotide polymorphisms (SNPs) on predefined severe adverse events in breast cancer (BC) patients receiving (neo-)adjuvant 5-fluorouracil (FU), epirubicin and cyclophosphamide (FEC) chemotherapy." | 7.79 | Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC). ( Belmans, A; Brouwers, B; Dieudonné, A; Hatse, S; Lambrechts, D; Neven, P; Paridaens, R; Schöffski, P; van Brussel, T; Vulsteke, C; Wildiers, H, 2013) |
| "Our primary objective was to determine the response rate; secondary objectives were to assess the toxicity rate, and disease-free and overall survival rates in patients with locally advanced breast cancer (LABC) receiving a cyclophosphamide (500 mg/m2), mitoxantrone (12 mg/m2) and 5-fluorouracil (500 mg/m2) (CMF) chemotherapy regimen." | 7.73 | Neoadjuvant chemotherapy with cyclophosphamide, mitoxantrone, and 5-fluorouracil in locally advanced breast cancer. ( Altundag, K; Atahan, L; Baltali, E; Cengiz, M; Erol, K; Guler, N; Onat, DA; Ozisik, Y; Sayek, I; Tekuzman, G, 2005) |
| "Following the encouraging results achieved with the oral fluoropyrimidine capecitabine in clinical trials, a named patient programme was initiated in the UK, through which patients with advanced breast cancer were prescribed capecitabine monotherapy." | 7.71 | Capecitabine named-patient programme for patients with advanced breast cancer. the UK experience. ( Breddy, J; Cameron, D; Chaturvedi, A; Hutcheon, A; Leonard, RC; Salazar, R; Twelves, C, 2002) |
| "The aim of the study was to define the maximum tolerated dose (MTD) of the combination of raltitrexed plus carmofur, and to evaluate the tolerability and efficacy of this combination in metastatic colorectal cancer." | 7.71 | A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer. ( Elomaa, I; Joensuu, H; Osterlund, P; Virkkunen, P, 2001) |
| "Toxicity and results of two different dose levels of chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in older (greater than 70 years) patients with advanced breast cancer were evaluated in a prospective (non-randomised) study." | 7.68 | Dose intensity of chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil in the elderly with advanced breast cancer. ( Beex, LV; Hermus, AR; Mignolet, F; Nooy, MA; Pieters, GF; van Hoesel, QG, 1992) |
| " We treated 40 evaluable patients with metastatic breast cancer and no prior exposure to chemotherapy with 5-fluorouracil, pirarubicin, and cyclophosphamide at 21-day intervals until reaching cumulative doses of 800 mg/m2 of pirarubicin, or the development of progressive disease." | 7.68 | Pirarubicin in combination chemotherapy for metastatic breast cancer. ( Buzdar, AU; Fraschini, G; Frye, D; Hortobagyi, GN; Ro, JS; Salewski, E; Tashima, CK; Theriault, RL; Walters, RS, 1990) |
| "Forty-one women with advanced breast cancer were treated with cyclophosphamide, methotrexate, 5-FU, and prednisone." | 7.67 | Sequential methotrexate and 5-FU in CMFP (cyclophosphamide, methotrexate, 5-FU, and prednisone) therapy for breast cancer. ( Cadman, EC; Cross, J; Glick, JH; Horton, J; Taylor, SG, 1984) |
| "Thirty consecutive patients with metastatic breast cancer previously untreated by chemotherapy were given high-dose cyclophosphamide (Cytoxan) and high-dose 5-fluorouracil (5-FU) as first-line therapy." | 7.67 | High-dose cyclophosphamide and high-dose 5-fluorouracil. A new first-line regimen for advanced breast cancer. ( Aguilera, J; Breau, JL; Israel, L, 1984) |
| "The authors assessed the value of protracted low-dose 5-fluorouracil (5-FU) infusion (250 mg/m2/day) in refractory breast cancer." | 7.67 | 5-Fluorouracil rechallenge by protracted infusion in refractory breast cancer. ( Holmes, FA; Hortobagyi, G; Jabboury, K, 1989) |
| "Capecitabine was administered at a dose of 1,250 mg/m(2) bid for 14 consecutive days in 3-week cycles, with dose modifications if necessary." | 6.73 | Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. ( Altorjai, G; Bartsch, R; Gnant, M; Mader, RM; Pluschnig, U; Rudas, M; Steger, GG; Wenzel, C; Zielinski, CC, 2007) |
| " Severe taxane-related toxic effects were more frequent in group A, while severe thrombocytopenia was low and present only in group A." | 6.73 | Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. ( Bafaloukos, D; Briasoulis, E; Dafni, U; Dimitrakakis, K; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Linardou, H; Makrantonakis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Pisanidis, N; Polichronis, A; Samantas, E; Skarlos, D; Stathopoulos, GP; Tzorakoeleftherakis, E; Varthalitis, I; Xiros, N, 2008) |
| "Patients with colorectal cancer (CRC) and liver metastases have a poor prognosis, but can benefit from perioperative chemotherapy and disease resection." | 6.73 | Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. ( Gruenberger, B; Gruenberger, T; Herbst, F; Scheithauer, W; Schueller, J; Tamandl, D; Zielinski, C, 2008) |
| " Studies of bimonthly regimens of high-dose leucovorin (LV) and 5-fluorouracil (5-FU) by continuous infusion combined with oxaliplatin (L-OHP) have shown encouraging response rates in patients not responding to a bimonthly LV/5-FU regimen." | 6.70 | Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study. ( Atanackovic, D; Corovic, A; Gruber, Y; Hegewisch-Becker, S; Hossfeld, DK; Nierhaus, A; Pichlmeier, U, 2002) |
| "Gemcitabine has demonstrated a good efficacy in number of tumor types." | 6.41 | [Gemcitabine and breast cancer]. ( Besse, B; Spano, JP, 2002) |
| "The purpose of this study was to examine the efficacy of a combination treatment of sequential irinotecan and doxifluridine, an intermediate of capecitabine, evaluated by the response rate and safety in patients with metastatic colorectal cancer." | 6.23 | A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer. ( Amano, M; Fukunaga, M; Ikeda, K; Ikeda, M; Ikenaga, M; Ishida, H; Kato, T; Mishima, H; Monden, M; Murata, K; Ohnishi, T; Ota, H; Sakamoto, J; Sekimoto, M; Tominaga, S, 2008) |
| " Docetaxel, cisplatin, 5-fluorouracil (DCF) is effective, but highly toxic regimen for advanced cases." | 5.36 | The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. ( Abali, H; Budakoglu, B; Güler, T; Odabaşi, H; Oksüzoğlu, B; Ozdemir, NY; Uncu, D; Zengin, N, 2010) |
| "Adverse events associated with 5-fluorouracil (5FU) based adjuvant therapy in colorectal cancer (CRC) patients may predict survival." | 5.19 | Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity? ( André, T; Bono, P; de Gramont, A; Hermunen, K; Österlund, P; Poussa, T; Quinaux, E; Soveri, LM, 2014) |
| " This study determined the maximum-tolerated dose (MTD), toxicity, and pharmacokinetics of irinotecan (CPT-11), capecitabine, and epirubicin in patients with metastatic adenocarcinoma of lung, breast, or gastrointestinal tract." | 5.13 | Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies. ( Becerra, CR; Frenkel, EP; Tavana, D; Tran, HT; Verma, UN; Williams, NS, 2008) |
| "gov ID: NCT00331097), early breast cancer patients, 65-79 years old, with average to high risk of recurrence, are randomly assigned to receive CMF (cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, fluorouracil 600 mg/m2, days 1-8) or docetaxel (35 mg/m2 days 1-8-15), every 4 weeks." | 5.13 | Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. ( Colozza, M; D'Aiuto, G; De Maio, E; de Matteis, A; De Placido, S; Di Rella, F; Gallo, C; Gori, S; Gravina, A; Labonia, V; Landi, G; Lauria, R; Morabito, A; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Rossi, E; Signoriello, G; Thomas, R, 2008) |
| " This phase I/II trial was carried out to evaluate the combination of capecitabine and the proteasome inhibitor bortezomib in anthracycline and/or taxane-pretreated patients with metastatic breast cancer." | 5.13 | A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. ( Brossart, P; Freier, W; Greil, R; Kiewe, P; Kühnhardt, D; Kümmel, S; Lange, W; Lehenbauer-Dehm, S; Niederle, N; Possinger, K; Preiss, J; Regierer, A; Schippinger, W; Schmid, P; Van de Velde, H, 2008) |
| "The aim of this study was to evaluate the effects of a combination of folinic acid, 5-fluorouracil (5FU) and irinotecan (FOLFIRI 1) administered every 2 weeks in a population of elderly subjects with advanced colorectal cancer." | 5.13 | Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study. ( Badetti, JL; Berdah, JF; Chamorey, E; Codoul, JF; François, E; Hébert, C; Lesbats, G; Mari, V; Teissier, E, 2008) |
| "This study was conducted to determine, in patients with advanced-stage breast cancer, the maximum tolerated dose (MTD) of capecitabine administered orally for 7 days followed by a 7-day rest (7/7), a schedule based on a mathematical method for the optimization of anticancer drug scheduling." | 5.13 | Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. ( Dugan, U; Edwards, C; Feigin, K; Hudis, C; Norton, L; Patil, S; Tan, KL; Theodoulou, M; Traina, TA, 2008) |
| "The aim of the study was to analyse the toxicity and health related quality of life (HRQoL) of breast cancer patients treated with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) and TAC (docetaxel, doxorubicin, cyclophosphamide) with and without primary prophylactic G-CSF (PPG)." | 5.12 | Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony sti ( Adrover, E; Antón, A; Arcusa, A; Calvo, L; del Prado, PM; Fernandez-Chacón, C; Grosse, R; Iglesias, L; Isla, D; Lluch, A; López-Vega, JM; Martín, M; Mel, JR; Muñoz, M; Ramos, M; Rodríguez-Lescure, A; Roset, M; Ruiz, A; Seguí, MA; Zaluski, J, 2006) |
| "This phase II randomised trial compares oxaliplatin plus protracted infusion of 5-fluorouracil (pviFOX) or oxaliplatin plus capecitabine (XELOX) in the first-line treatment of advanced colorectal cancer (ACRC)." | 5.12 | Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial). ( Ballardini, P; Di Fabio, F; Gentile, AL; Giaquinta, S; Lelli, G; Martoni, AA; Mutri, V; Piana, E; Pinto, C; Rojas Llimpe, FL, 2006) |
| "This multicentre phase I/II study was designed to determine the maximum tolerated dose of irinotecan when combined with 5-fluorouracil and folinic acid according to the Mayo Clinic schedule and to evaluate the activity of this combination as first-line therapy in patients with advanced colorectal cancer." | 5.11 | Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. ( Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J, 2004) |
| "Combination therapy of irinotecan, folinic acid (FA) and 5-fluorouracil (5-FU) has been proven to be highly effective for the treatment of metastatic colorectal cancer." | 5.11 | Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. ( Adami, B; Galle, PR; Heike, M; Hohl, H; Höhler, T; Klein, O; Moehler, M; Schroeder, M; Siebler, J; Steinmann, S; Teufel, A; Zanke, C, 2004) |
| "The authors present the Hungarian interim analysis and experience with the BCIRG 001 randomized, multicentric, phase III clinical trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) and FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer patients." | 5.10 | [Hungarian experience with docetaxel combination (TAC) in the adjuvant treatment of breast cancer. Results of BCIRG 001 randomized, multicentric, phase III trial]. ( Boér, K; Juhos, E; Láng, I; Pintér, T; Szántó, J, 2003) |
| "The aim of this study was to evaluate the toxicity and efficacy of combination chemotherapy with weekly 24-h continuous infusion of 5-fluorouracil (5-FU)/folinic acid, weekly paclitaxel and 3-weekly cisplatin in patients with unresectable, locally advanced or metastatic gastric adenocarcinoma." | 5.10 | Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. ( Baronius, W; Bokemeyer, C; Haag, C; Hartmann, JT; Hempel, V; Honecker, F; Kanz, L; Kollmannsberger, C; Quietzsch, D; Schroeder, M; Spott, C, 2002) |
| "The aim of this prospective study was to assess the efficacy, clinical benefit and safety of CPT-11 (irinotecan) in patients with stringently-defined 5-fluorouracil-resistant metastatic colorectal cancer (CRC)." | 5.09 | Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). ( Alexopoulos, CG; Blanc, C; Bleiberg, H; Blijham, GH; Cholet, P; Cote, C; Cunningham, D; Dirix, L; Fillet, G; Hérait, P; Levi, F; Panagos, G; Punt, CJ; Symann, M; Ten Bokkel Huinink, WW; Unger, C; Van Cutsem, E; Van Groeningen, C; Vannetzel, JM; Wils, J, 1999) |
| "This phase-II study was conducted to investigate the potential benefit from the addition of mitomycin to a conventional anthracycline-cisplatin- and 5-fluorouracil-based chemotherapy for recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type (UCNT)." | 5.09 | Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type. ( Alonso, S; Armand, JP; Chouaki, N; Cortès-Funes, H; Cvitkovic, E; Fandi, A; Hasbini, A; Lianes, P; Mahjoubi, R; Raymond, E; Taamma, A, 1999) |
| "Oxaliplatin is a novel platinum derivative, which, combined with 5-fluorouracil (5-FU), and folinic acid (FA), demonstrates synergistic activity in metastatic colorectal cancer (MCC)." | 5.09 | Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study. ( Fountzilas, G; Janinis, J; Papagianopoulos, P; Papakostas, P; Samelis, G; Skarlos, D, 2000) |
| "We have reported a 33% partial response rate with acceptable toxicity using weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) and leucovorin (LV) in patients with far advanced biliary tract cancers (BTC)." | 5.09 | Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas. ( Chen, JS; Jan, YY; Liau, CT; Lin, YC, 2001) |
| "To determine whether a combination chemotherapy regimen that contains epirubicin (fluorouracil, epirubicin, and cyclophosphamide [FEC]) is superior to the standard cyclophosphamide, methotrexate, and fluorouracil (CMF) combination in premenopausal women with axillary node-positive operable breast cancer." | 5.08 | Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collab ( Aapro, M; Amadori, D; Bliss, JM; Chilvers, CE; Coombes, G; Coombes, RC; Espié, M; Ferreira, EP; Gambrosier, P; Marty, M; McArdle, C; Morvan, F; Pérez-López, FR; Richards, M; Vassilopoulos, P; Villar-Grimalt, A; Wils, J; Woods, EM, 1996) |
| " 439 patients were entered into a phase III trial comparing a novel thymidylate synthase (TS) inhibitor Tomudex (raltitrexed, formerly ZD1694) with 5-FU and leucovorin (LV) for the treatment of advanced colorectal cancer." | 5.08 | Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group. ( Kerr, D; Palmer, M; Seymour, L; Zalcberg, J, 1998) |
| "32 consecutive early breast cancer patients were treated to evaluate the feasibility of an accelerated CEF regimen (cyclophosphamide 600 mg/m2, epirubicin 60 mg/m2 and 5-fluorouracil 600 mg/m2) given intravenously every 2 weeks for six cycles together with granulocyte colony stimulating factor, 5 micrograms/kg/day subcutaneously from day 4 to day 11." | 5.07 | A pilot study of accelerated cyclophosphamide, epirubicin and 5-fluorouracil plus granulocyte colony stimulating factor as adjuvant therapy in early breast cancer. ( Canavese, G; Catturich, A; Del Mastro, L; Garrone, O; Guenzi, M; Rosso, R; Sertoli, MR; Venturini, M, 1994) |
| "In an attempt to improve the primary treatment of malignant gliomas we used a concomitant 6-week course of chemoradiotherapy with 5 fluorouracil (5 FU) and hydroxyurea (HU) in 24 adults with anaplastic astrocytoma (AA) (7 cases) or glioblastomas (GLB) (17 cases)." | 5.07 | Pilot study of 6 weeks of chemoradiotherapy with 5 FU and hydroxyurea in malignant gliomas. ( Armand, JP; Cioloca, C; Constans, JP; Cvitkovic, FB; Haie-Meder, C; Maugis, N; Papadimitrakopoulou, V, 1993) |
| "Twenty-two patients with previously untreated metastatic breast cancer and nineteen patients with refractory metastatic breast cancer were treated with trimetrexate (TMTX)." | 5.07 | Trimetrexate in untreated and previously treated patients with metastatic breast cancer: a Cancer and Leukemia Group B study. ( Carey, RW; Clamon, GH; Costanza, ME; Dawson, NA; Korzun, AH; Norton, L; Pollak, M; Vogelzang, NJ, 1991) |
| "The French Epirubicin Study Group carried out a randomized trial comparing epirubicin alone 75 mg/m2 with fluorouracil (5FU) 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 50 mg/m2 (FEC 50) and 5FU 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 75 mg/m2 (FEC 75) as first treatment for advanced breast cancer patients." | 5.07 | A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group. ( , 1991) |
| "The FAM combination with the simultaneous administration of 5-fluorouracil, doxorubicin, and mitomycin C is considered standard chemotherapy for gastric adenocarcinoma." | 5.05 | Drug combinations in the treatment of gastric adenocarcinoma: a randomized Southwest Oncology Group study. ( Athens, J; Chen, TT; Costanzi, JJ; Haas, C; Heilbrun, LK; McDonald, B; Oishi, N; Panettiere, FJ; Talley, RW, 1984) |
| "Data on 162 women (90 premenopausal and 72 postmenopausal) with metastatic breast cancer randomized to receive cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF) on two Eastern Cooperative Oncology Group (ECOG) protocols were analyzed." | 5.05 | The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Carbone, PP; Cummings, FJ; Falkson, G; Falkson, HC; Gelman, RS; Tormey, DC, 1985) |
| "After mastectomy, 265 postmenopausal patients with node-positive breast cancer were stratified according to pathologic nodal status and estrogen-receptor (ER) status and randomized to receive either 12 cycles of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP), or CMFP plus tamoxifen (CMFPT), or observation alone." | 5.05 | Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study. ( Bennett, JM; Carbone, PP; Cummings, F; Falkson, G; Kalish, LA; Olson, JE; Taylor, SG; Tormey, DC, 1985) |
| ", Nutley, NJ) is an orally administered fluoropyrimidine carbamate that serves as a prodrug of 5-fluorouracil (5-FU), an integral component of chemotherapy (CT) regimens for metastatic colorectal cancer (mCRC)." | 4.86 | Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer. ( Boehm, KA; Cartwright, T; McCollum, D, 2010) |
| "Fluorouracil (5-FU) continuous infusion is superior to 5-FU bolus in patients with advanced colorectal cancer, but the survival difference between the two treatments is small and, therefore, the difference in toxicity profile is crucial in choosing a treatment for individual patients." | 4.80 | Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. ( Benedetti, J; Brufman, G; Buyse, M; Fryer, J; Hansen, R; Isacson, R; Laplanche, A; Leichman, C; Lévy, E; Lokich, J; Macdonald, J; Pater, J; Piedbois, P; Pignon, JP; Quinaux, E; Rougier, P; Ryan, L; Thirion, P; Weinerman, B; Zee, B, 1998) |
| "To assess the impact of single-nucleotide polymorphisms (SNPs) on predefined severe adverse events in breast cancer (BC) patients receiving (neo-)adjuvant 5-fluorouracil (FU), epirubicin and cyclophosphamide (FEC) chemotherapy." | 3.79 | Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC). ( Belmans, A; Brouwers, B; Dieudonné, A; Hatse, S; Lambrechts, D; Neven, P; Paridaens, R; Schöffski, P; van Brussel, T; Vulsteke, C; Wildiers, H, 2013) |
| "Our primary objective was to determine the response rate; secondary objectives were to assess the toxicity rate, and disease-free and overall survival rates in patients with locally advanced breast cancer (LABC) receiving a cyclophosphamide (500 mg/m2), mitoxantrone (12 mg/m2) and 5-fluorouracil (500 mg/m2) (CMF) chemotherapy regimen." | 3.73 | Neoadjuvant chemotherapy with cyclophosphamide, mitoxantrone, and 5-fluorouracil in locally advanced breast cancer. ( Altundag, K; Atahan, L; Baltali, E; Cengiz, M; Erol, K; Guler, N; Onat, DA; Ozisik, Y; Sayek, I; Tekuzman, G, 2005) |
| "Few data are available on compliance and safety of adjuvant chemotherapy when indicated in elderly breast cancer patients; CMF (cyclophosphamide, methotrexate, fluorouracil) can be reasonably considered the most widely accepted standard of treatment." | 3.73 | Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience. ( Amabile, G; Capasso, I; D'Aiuto, G; De Maio, E; de Matteis, A; Di Maio, M; Elmo, M; Gravina, A; Labonia, V; Landi, G; Morrica, B; Nuzzo, F; Pacilio, C; Perrone, F; Rinaldo, M; Rossi, E, 2005) |
| "Following the encouraging results achieved with the oral fluoropyrimidine capecitabine in clinical trials, a named patient programme was initiated in the UK, through which patients with advanced breast cancer were prescribed capecitabine monotherapy." | 3.71 | Capecitabine named-patient programme for patients with advanced breast cancer. the UK experience. ( Breddy, J; Cameron, D; Chaturvedi, A; Hutcheon, A; Leonard, RC; Salazar, R; Twelves, C, 2002) |
| "The aim of the study was to define the maximum tolerated dose (MTD) of the combination of raltitrexed plus carmofur, and to evaluate the tolerability and efficacy of this combination in metastatic colorectal cancer." | 3.71 | A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer. ( Elomaa, I; Joensuu, H; Osterlund, P; Virkkunen, P, 2001) |
| "Toxicity and results of two different dose levels of chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in older (greater than 70 years) patients with advanced breast cancer were evaluated in a prospective (non-randomised) study." | 3.68 | Dose intensity of chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil in the elderly with advanced breast cancer. ( Beex, LV; Hermus, AR; Mignolet, F; Nooy, MA; Pieters, GF; van Hoesel, QG, 1992) |
| " We treated 40 evaluable patients with metastatic breast cancer and no prior exposure to chemotherapy with 5-fluorouracil, pirarubicin, and cyclophosphamide at 21-day intervals until reaching cumulative doses of 800 mg/m2 of pirarubicin, or the development of progressive disease." | 3.68 | Pirarubicin in combination chemotherapy for metastatic breast cancer. ( Buzdar, AU; Fraschini, G; Frye, D; Hortobagyi, GN; Ro, JS; Salewski, E; Tashima, CK; Theriault, RL; Walters, RS, 1990) |
| "Fifty-one patients with metastatic adenocarcinoma received Folinic Acid (FA) combined with 5-Fluorouracil (5FU) in a Phase I-II clinical trial." | 3.67 | 5-Fluorouracil and folinic acid: a Phase I-II trial in gastrointestinal malignancy. ( Budd, GT; Bukowski, RM; Cunningham, J; Purvis, J; Weick, JK, 1984) |
| "Forty-one women with advanced breast cancer were treated with cyclophosphamide, methotrexate, 5-FU, and prednisone." | 3.67 | Sequential methotrexate and 5-FU in CMFP (cyclophosphamide, methotrexate, 5-FU, and prednisone) therapy for breast cancer. ( Cadman, EC; Cross, J; Glick, JH; Horton, J; Taylor, SG, 1984) |
| "Thirty consecutive patients with metastatic breast cancer previously untreated by chemotherapy were given high-dose cyclophosphamide (Cytoxan) and high-dose 5-fluorouracil (5-FU) as first-line therapy." | 3.67 | High-dose cyclophosphamide and high-dose 5-fluorouracil. A new first-line regimen for advanced breast cancer. ( Aguilera, J; Breau, JL; Israel, L, 1984) |
| "The authors assessed the value of protracted low-dose 5-fluorouracil (5-FU) infusion (250 mg/m2/day) in refractory breast cancer." | 3.67 | 5-Fluorouracil rechallenge by protracted infusion in refractory breast cancer. ( Holmes, FA; Hortobagyi, G; Jabboury, K, 1989) |
| "Seventy patients with poor prognosis, metastatic breast cancer were treated with FUVAC induction chemotherapy (5-fluorouracil, vinblastine, Adriamycin [doxorubicin] and cyclophosphamide)." | 3.67 | Combination chemotherapy and systemic irradiation consolidation for poor prognosis breast cancer. ( Fabian, CJ; Goldberg, RS; Griffin, BR; Hammond, N; Hynes, H; Livingston, RB; Rivkin, SE; Schulman, S; Tranum, BL, 1987) |
| "Dose modification of chemotherapy for metastatic colorectal cancer (MCRC) is often needed, especially in second-line and later-line treatments due to adverse events of previous treatment and poor patient condition." | 2.90 | Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer. ( Aikawa, T; Akashi, K; Ariyama, H; Baba, E; Doi, Y; Esaki, T; Ito, M; Kobayashi, K; Kusaba, H; Makiyama, A; Mitsugi, K; Shimokawa, H; Takayoshi, K; Tsuchihashi, K; Uenomachi, M; Yoshihiro, T, 2019) |
| "The aim of the study was to assess the toxicity and the clinical activity of biweekly oxaliplatin (OXA) in combination with continuous infusional 5-fluorouracil (5-FU) and leucovorin (LV) administered every 2 weeks (modified FOLFOX-4 regimen) in elderly patients with advanced gastric cancer (AGC)." | 2.73 | Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer. ( Fu, Z; Guan, F; Guo, QS; Liu, ZF; Wang, MY; Yang, XG; Zhang, XQ, 2008) |
| "Capecitabine was administered at a dose of 1,250 mg/m(2) bid for 14 consecutive days in 3-week cycles, with dose modifications if necessary." | 2.73 | Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. ( Altorjai, G; Bartsch, R; Gnant, M; Mader, RM; Pluschnig, U; Rudas, M; Steger, GG; Wenzel, C; Zielinski, CC, 2007) |
| "Gemcitabine was given by intravenous administration over 30 min on day 1, week 1 and day 8, week 2." | 2.73 | A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma. ( Amato, RJ; Khan, M, 2008) |
| "We hypothesised that gastric cancer outcome could be improved with more effective and intensified postoperative chemoradiotherapy." | 2.73 | Postoperative chemoradiotherapy in gastric cancer -- a Phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy. ( Bartelink, H; Boot, H; Cats, A; Dubbelman, R; Jansen, EP; Verheij, M, 2007) |
| " Severe taxane-related toxic effects were more frequent in group A, while severe thrombocytopenia was low and present only in group A." | 2.73 | Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. ( Bafaloukos, D; Briasoulis, E; Dafni, U; Dimitrakakis, K; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Linardou, H; Makrantonakis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Pisanidis, N; Polichronis, A; Samantas, E; Skarlos, D; Stathopoulos, GP; Tzorakoeleftherakis, E; Varthalitis, I; Xiros, N, 2008) |
| "Complete surgical resection of gastric cancer is potentially curative, but long-term survival is poor." | 2.73 | Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. ( Antimi, M; Antonuzzo, L; Arcangeli, A; Banducci, S; Bellini, V; Biagioni, F; Bianchini, D; Bilancia, D; Bisagni, G; Biscottini, B; Boni, C; Bracci, R; Bravi, S; Bruno, L; Cabassi, A; Camera, S; Camisa, R; Canaletti, R; Carboni, M; Carlini, P; Carroccio, R; Cascinu, S; Catalano, G; Catalano, V; Cavalli, C; Cesari, M; Cognetti, F; Contu, A; Corgna, E; Cortesi, E; Croce, E; Dalla Mola, A; De Filippis, S; De Stefanis, M; Di Costanzo, F; Dinota, A; Enzo, MR; Farris, A; Figoli, F; Floriani, I; Foa, P; Fornarini, G; Francavilla, F; Frignano, M; Gasperoni, S; Gilli, G; Giunta, A; Grigniani, F; Ionta, MT; Italia, M; Labianca, R; Lastraioli, E; Leoni, M; Lungarotti, F; Luppi, G; Manzione, L; Masoni, L; Massidda, B; Mela, M; Messerini, L; Monzio Compagnoni, B; Muscogiuri, A; Natalini, G; Nelli, F; Nicolosi, A; Oldani, S; Olgiati, A; Olivetti, A; Orselli, G; Pandolfi, U; Papiani, G; Pazzola, A; Piga, A; Pisani Leretti, A; Porrozzi, S; Recchia, F; Romiti, A; Rondini, E; Rossetti, R; Rovei, R; Saggese, M; Sarobba, MG; Scipioni, L; Strafiuso, G; Tomao, S; Tonato, M; Torri, V; Trignano, M; Zironi, S, 2008) |
| "To test the efficacy and safety of pharmacokinetic modulating chemotherapy combined with cisplatin (PMC-cisplatin) as induction chemotherapy (ICT) before definitive treatment in patients with respectable locally advanced head and neck squamous cell carcinoma (HNSCC)." | 2.73 | Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study. ( Chang, PM; Chang, SY; Chen, PM; Chu, PY; Huang, JL; Tai, SK; Tsai, TL; Wang, LW; Wang, YF; Yang, MH, 2008) |
| "Patients with colorectal cancer (CRC) and liver metastases have a poor prognosis, but can benefit from perioperative chemotherapy and disease resection." | 2.73 | Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. ( Gruenberger, B; Gruenberger, T; Herbst, F; Scheithauer, W; Schueller, J; Tamandl, D; Zielinski, C, 2008) |
| " A phase I, open-label dose-escalating study was performed to determine the maximum tolerated dose (MTD) of BBR 3464 administered in combination with protracted venous infusional (PVI) 5-fluorouracil (5-FU) for up to six courses in patients with locally advanced and/or metastatic cancer." | 2.71 | A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer. ( Bisset, D; Boyle, D; Camboni, G; Cassidy, J; Edwards, C; Gourley, C; Jodrell, D; Samuel, L; Young, A, 2004) |
| "Metastatic renal cell carcinoma (RCC) has modest response rates to chemotherapy with gemcitabine and 5-fluorouracil (5-FU)." | 2.71 | A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma. ( Rini, BI; Small, EJ; Weinberg, V, 2005) |
| "Fifteen patients with LA pancreatic cancer received three-dimensional conformal XRT to a dose of 50." | 2.71 | Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. ( Blanquicett, C; Carpenter, M; Diasio, RB; Eloubeidi, MA; Fiveash, J; Johnson, MR; Russo, S; Saif, MW; Steg, A; Thornton, J, 2005) |
| " Studies of bimonthly regimens of high-dose leucovorin (LV) and 5-fluorouracil (5-FU) by continuous infusion combined with oxaliplatin (L-OHP) have shown encouraging response rates in patients not responding to a bimonthly LV/5-FU regimen." | 2.70 | Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study. ( Atanackovic, D; Corovic, A; Gruber, Y; Hegewisch-Becker, S; Hossfeld, DK; Nierhaus, A; Pichlmeier, U, 2002) |
| " 5-FU dosage was fixed at 1,600 mg/m2 while docetaxel was evaluated at weekly 1-hour infusion dosages of 30, 40 and 50 mg/m2 to determine the MTD." | 2.70 | A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer. ( Chang, JY; Chen, LT; Chung, TR; Jan, CM; Liu, JM; Liu, TW; Shiah, HS; Whang-Peng, J; Wu, CW, 2002) |
| "Raltitrexed has been shown to be devoid of clinical activity against SCCHN when used alone; however, both preclinical and early clinical data regarding the combination raltitrexed-CDDP hold promise." | 2.70 | Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study. ( Avallone, A; Caponigro, F; Comella, G; Comella, P; De Lucia, L; De Rosa, P; De Rosa, V; Rosati, G, 2002) |
| "Malignant pleural mesothelioma is associated with a poor prognosis because of its resistance to treatment." | 2.69 | Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura. ( Astoul, P; Boutin, C; Kasseyet, S, 1999) |
| " The recommended 5-FU dosage for phase II evaluations is 1,250 mg/m(2)/wk for 3 weeks every 4 weeks with the intensified PN401 dose schedule (schedule 2)." | 2.69 | Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies. ( Campbell, E; Davidson, K; Diab, SG; Drengler, RL; Eckhardt, SG; Garner, AM; Hammond, LA; Hidalgo, M; Louie, A; O'Neil, JD; Rodriguez, G; Rowinsky, EK; Villalona-Calero, MA; von Borstel, R; Von Hoff, DD; Weiss, G, 2000) |
| "To determine the dose-limiting toxicity of CPT-11 in combination with oxaliplatin, and the maximal tolerated dose (MTD) and the recommended dose (RD) of CPT-11 using an every two weeks schedule." | 2.69 | Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients. ( Cvitkovic, E; Di Palma, M; Goldwasser, F; Gross-Goupil, M; Marceau-Suissa, J; Misset, JL; Tigaud, JM; Wasserman, E; Yovine, A, 2000) |
| "Twenty patients with stage IV squamous cell carcinoma of head and neck were studied." | 2.68 | Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy. ( Chan, WK; Chang, CY; Chao, JY; Chen, CH; Chen, KY; Chen, SY; Chi, KH; Chow, KC; Yen, SH, 1995) |
| "In advanced breast cancer high-dose consolidation chemotherapy with haematological rescue has resulted in prolonged disease free and overall survival in a small percentage of patients." | 2.67 | Dose-escalating induction chemotherapy supported by lenograstim preceding high-dose consolidation chemotherapy for advanced breast cancer. Selection of the most acceptable regimen to induce maximal tumor response and investigation of the optimal time to c ( Baumann, I; de Wynter, EA; Dexter, TM; Lange, C; Luft, T; Morgenstern, GR; Ranson, M; Testa, NG; Van Hoef, ME; Yvers, A, 1994) |
| "Fifty-seven Dukes C colorectal cancer patients were given 5-fluorouracil-interferon-alpha 2b adjuvant treatment from October 1986 to September 1990." | 2.67 | 5-Fluorouracil-interferon-alpha 2b adjuvant treatment of Dukes C colorectal cancer. ( Cremone, L; Espinosa, A; Faiella, F; Frasci, G; Leone, F; Monaco, M; Persico, G; Sapio, U, 1994) |
| "Grade 3 infections were seen in 9 cycles (5%)." | 2.67 | Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. ( Chevallier, B; Chollet, P; Hurteloup, P; Olivier, JP; Roche, H, 1993) |
| " The recommended dosage schedule with this technique is cisplatin 25 mg/m2 and FU 750 mg total dose IP with FU 500 mg/m2 as a continuous 24-hour infusion daily for days 1 to 4." | 2.67 | Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer. ( Atiq, OT; Brennan, M; Kelsen, DP; Lin, S; Niedzwiecki, D; Saltz, L; Shiu, MH; Tong, W; Toomasi, F; Trochanowski, B, 1993) |
| " On closer examination, the agents that appear to be responsible for these especially adverse effects are methotrexate and methyl-CCNU." | 2.65 | Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group. ( Begg, CB; Carbone, PP, 1983) |
| "Patients with advanced colorectal cancer and no prior chemotherapy were randomized to six treatment regimens: A) fluorouracil (FU) alone; B) FU + hydroxyurea (HU); C) semustine (SE) + dacarbazine (DA); D) FU + HU alternating with SE + DA; E) SE + razoxane (RA); F) mitomycin (MI) + DA." | 2.65 | Chemotherapy of advanced colorectal carcinoma: fluorouracil alone vs. two drug combinations using fluorouracil, hydroxyurea, semustine, dacarbazine, razoxane, and mitomycin. A phase III trial by the Eastern Cooperative Oncology Group (EST: 1278). ( Engstrom, PF; Klaassen, DJ; MacIntyre, JM; Mittelman, A, 1984) |
| " In Japan, S-1 in combination with cisplatin is the recommended first-line treatment in patients with gastric cancer." | 2.55 | New Perspectives in the Treatment of Advanced Gastric Cancer: S-1 as a Novel Oral 5-FU Therapy in Combination with Cisplatin. ( Heinemann, V; Lorenzen, S; Mahlberg, R; Möhler, M; Pfeiffer, P; Thuss-Patience, P, 2017) |
| "Head and neck cancer, mostly squamous cell carcinoma, ranks sixth among the most common cancers." | 2.49 | Addition of taxane to induction therapy in head and neck malignancies: a systematic review and meta-analysis of randomized controlled trials. ( Ben-Aharon, I; Perl, G; Popovtzer, A; Stemmer, SM; Vidal, L, 2013) |
| "A total number of 53 metastatic colorectal cancer patients were treated with BEV-CAPIRI regimen." | 2.46 | Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer. ( Bozkurt, MT; Cirak, Y; Degirmenci, M; Demir Piskin, G; Durusoy, R; Gorumlu, G; Karabulut, B; Karaca, B; Sanli, UA; Tunali, D; Uslu, R, 2010) |
| "The late diagnosis of pancreatic cancer, at a locally advanced and metastatic stage explains in part its poor prognosis." | 2.41 | [Gemcitabine and pancreatic cancer]. ( Azria, D; Prost, P; Ychou, M, 2002) |
| "Gemcitabine has demonstrated a good efficacy in number of tumor types." | 2.41 | [Gemcitabine and breast cancer]. ( Besse, B; Spano, JP, 2002) |
| "Alopecia was observed in 60% of patients." | 1.62 | Toxicity profile of taxanes in Tunisian cancer patients: A retrospective study of 90 cases. ( Ayari, J; Balti, M; Ben Abdallah, I; Ben Hassen, M; Ben Nasr, S; Doghri, Y; Fendri, S; Haddaoui, A; Trigui, E; Zribi, A, 2021) |
| "Acute hematotoxicity (G3, 4, 5 according to Common Terminology Criteria for Adverse Events - CTCAE) was significantly associated with the concomitant chemoradiotherapy (P = 0." | 1.56 | Haematotoxicity in IMRT/VMAT curatively treated anal cancer. ( Drbohlavová, T; Jirkovská, M; Lohynská, R; Malinová, B; Mazaná, E; Nýdlová, A; Stankušová, H; Veselský, T, 2020) |
| " Severe (grade ≥III) toxicity in DPYD variant allele carriers receiving upfront FP dose reductions according to pharmacogenetic dosing guidelines and DPYD variant allele carriers not receiving FP dose reductions was compared with DPYD wild-type patients receiving standard dose of FPs in CRT." | 1.48 | Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers. ( Cecchin, E; Dreussi, E; Fiocco, M; Gelderblom, H; Guchelaar, HJ; Henricks, LM; Lunenburg, CATC; Meulendijks, D; Peters, FP; Schellens, JHM; Swen, JJ; Toffoli, G, 2018) |
| " This treatment should be considered regardless of patients' age alone, but consideration should be given to the capacity of patients to tolerate adverse events." | 1.40 | Toxicity of oxaliplatin plus fluorouracil/leucovorin adjuvant chemotherapy in elderly patients with stage III colon cancer: a population-based study. ( Bedenne, L; Bouvier, AM; Faivre, J; Hamza, S; Lepage, C; Rollot, F, 2014) |
| "We analyzed 120 rectal cancer patients treated with neoadjuvant pelvic radiotherapy (PRT) with concurrent 5-fluorouracil-based chemotherapy." | 1.40 | Clinical and dosimetric predictors of acute hematologic toxicity in rectal cancer patients undergoing chemoradiotherapy. ( Apte, A; Deasy, JO; Goodman, KA; Oh, JH; Son, CH; Yang, TJ, 2014) |
| " Grade 3/4 adverse events were: neutropenia (54." | 1.39 | Safety and efficacy of modified FOLFOX6 plus high-dose bevacizumab in second-line or later treatment of patients with metastatic colorectal cancer. ( Maruyama, S; Takii, Y, 2013) |
| "Chemoradiation for anal cancer yields effective tumor control, but is associated with significant acute toxicity." | 1.38 | Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. ( Blaszkowsky, LS; Coen, JJ; Hartshorn, K; Hong, TS; Kachnic, LA; Kwak, EL; Ryan, DP; Tsai, HK; Willins, JD, 2012) |
| "Patients diagnosed with stage III colon cancer in 1991 to 2005 were identified from the Surveillance, Epidemiology, and End Results-Medicare database." | 1.38 | Adjuvant chemotherapy and risk of gastrointestinal, hematologic, and cardiac toxicities in elderly patients with stage III colon cancer. ( Chan, W; Delclos, GP; Du, XL; Hu, CY, 2012) |
| " Docetaxel, cisplatin, 5-fluorouracil (DCF) is effective, but highly toxic regimen for advanced cases." | 1.36 | The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. ( Abali, H; Budakoglu, B; Güler, T; Odabaşi, H; Oksüzoğlu, B; Ozdemir, NY; Uncu, D; Zengin, N, 2010) |
| "All 35 patients had metastatic pancreatic cancer (94% liver, 6% lung sites)." | 1.35 | The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. ( Andrade, R; Chabot, J; Desai, M; Fine, RL; Fogelman, DR; Guba, S; Schreibman, SM; Sherman, W; Strauss, J, 2008) |
| " CL(CR) should be considered when determining chemotherapy dosage in the elderly." | 1.33 | Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer. ( Brogan, K; Howard, J; Hudis, C; Hurria, A; Jakubowski, A; Norton, L; Panageas, KS; Pearce, C, 2005) |
| "Body weight was measured once a week." | 1.32 | Protective effects of glutathione on 5-fluorouracil-induced myelosuppression in mice. ( Hara, T; Kakuni, M; Kimoto, N; Kojima, S; Mizutani, M; Sato, H; Suzuki, K; Takaba, K; Takeda, T, 2003) |
| "The prognosis of locally advanced cervix cancers is poor with metastatic and local recurrence risks." | 1.31 | [Chemoradiotherapy in locally advanced cancers of the uterine neck. Retrospective study of 92 patients treated at the Institute Curie between 1986 and 1998]]. ( Beuzeboc, P; Chauveinc, L; Clough, KB; Cosset, JM; de la Rochefordière, A; Guyonnet, M; Mouret-Fourme, E; Nguyen, D, 2002) |
| "In the patients with squamous cell carcinoma, 100 mg/m2 of cisplatin was infused intravenously, followed immediately by five consecutive daily administrations of 5-fluorouracil, 1,000 mg/m2/day, each infused intravenously over 24 hr." | 1.31 | Concurrent chemotherapy and radiotherapy in invasive cervical cancer patients with high risk factors. ( Kim, GE; Kim, SN; Kim, SW; Park, TK; Suh, CO, 2000) |
| "Stage II patients with breast carcinoma who had undergone lumpectomy." | 1.28 | Adjuvant therapy of stage II breast cancer treated with CMFVP, radiation therapy and VATH following lumpectomy. A pilot trial. ( Allen, S; Bosworth, H; Budman, D; Lehrman, D; Lichtman, SM; Schulman, P; Vinciguerra, V; Weiselberg, L; Weiss, R, 1991) |
| "To determine the maximum tolerated dose of 5-fluorouracil administered as a 120-hour continuous intravenous infusion to pediatric patients, we performed a phase I study using a starting dosage of 900 mg/m2/day." | 1.28 | Phase I study of a 120-hour continuous intravenous infusion of 5-fluorouracil in pediatric patients with recurrent solid tumors: a Pediatric Oncology Group study. ( Bell, B; Brecher, ML; Cushing, B; Green, DM; Krischer, JP; Whitehead, VM, 1990) |
| "Twenty-three patients with advanced colorectal cancer were treated with folinic acid (200 mg/m2/day 1-5 IV bolus injection) and 5-fluorouracil (400 mg/m2/day 1-5 IV in 15 minutes) every 28 days." | 1.27 | High-dose folinic acid and 5-fluorouracil in advanced colorectal cancer. ( Bartolucci, R; Brugia, M; Buzzi, F; Di Costanzo, F; Padalino, D, 1988) |
| " 5-FU dosage was decreased in ten patients (36%) for grade 2 or greater stomatitis or diarrhea." | 1.27 | A phase I-II trial of carboplatin and 5-fluorouracil combination chemotherapy in advanced carcinoma of the head and neck. ( Forastiere, AA; Goren, MP; Kudla-Hatch, V; Natale, RB; Takasugi, BJ; Vogel, WC, 1987) |
| "Allopurinol has been shown to ameliorate the myelotoxicity of 5-fluorouracil (5-FU) given as an infusion." | 1.27 | Failure of allopurinol to provide clinically significant protection against the hematologic toxicity of a bolus 5-FU schedule. ( Ahmann, FR; Garewal, H, 1986) |
| " Since toxicity is a prominent impediment, the possibility of therapeutic synergy may perhaps be explored at drastically reduced doses of PALA, combined with other modulating measures." | 1.27 | Weekly 5-fluorouracil combined with PALA: toxic and therapeutic effects in colorectal cancer. ( Camacho, FJ; Engstrom, PF; Green, MD; Greenwald, ES; Kaplan, BH; Muggia, FM; Wernz, JC, 1987) |
| "Thirty patients with squamous cell carcinoma of the head and neck were treated with a combination of cisplatin (20 mg/m2) and 5-FU (400-200 mg/m2) by iv push on Days 1-5 every 21 days." | 1.27 | Phase I-II trial with cisplatin and 5-FU in recurrent head and neck cancer: an effective outpatient schedule. ( Grimaldi, A; Margarino, G; Merlano, M; Rosso, R; Tatarek, R, 1985) |
| "Stomatitis was the predominant dose-limiting toxicity (22% grade 1, 19% grade 2, and 27% grade 3 toxicity)." | 1.26 | Allopurinol modulation of fluorouracil toxicity. ( Fox, RM; Piper, AA; Sampson, D; Tattersall, MH; Woods, RL, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 33 (20.25) | 18.7374 |
| 1990's | 29 (17.79) | 18.2507 |
| 2000's | 66 (40.49) | 29.6817 |
| 2010's | 32 (19.63) | 24.3611 |
| 2020's | 3 (1.84) | 2.80 |
| Authors | Studies |
|---|---|
| Lohynská, R | 1 |
| Nýdlová, A | 1 |
| Drbohlavová, T | 1 |
| Mazaná, E | 1 |
| Jirkovská, M | 1 |
| Veselský, T | 1 |
| Malinová, B | 1 |
| Stankušová, H | 1 |
| Ben Nasr, S | 1 |
| Zribi, A | 1 |
| Ben Hassen, M | 1 |
| Doghri, Y | 1 |
| Ben Abdallah, I | 1 |
| Trigui, E | 1 |
| Fendri, S | 1 |
| Ayari, J | 1 |
| Balti, M | 1 |
| Haddaoui, A | 1 |
| Gürler, F | 1 |
| İlhan, A | 1 |
| Güven, DC | 1 |
| Turhan, O | 1 |
| Kurt İnci, B | 1 |
| Sütçüoğlu, O | 1 |
| Yildiz, F | 1 |
| Arik, Z | 1 |
| Öksüzoğlu, B | 2 |
| Yalçin, Ş | 1 |
| Özdemir, N | 1 |
| Yazici, O | 1 |
| Özet, A | 1 |
| Matsumoto, Y | 1 |
| Zhou, Q | 1 |
| Kamimura, K | 1 |
| Moriyama, M | 1 |
| Saijo, Y | 1 |
| Bachet, JB | 1 |
| Lucidarme, O | 1 |
| Levache, CB | 1 |
| Barbier, E | 1 |
| Raoul, JL | 1 |
| Lecomte, T | 1 |
| Desauw, C | 1 |
| Brocard, F | 1 |
| Pernot, S | 1 |
| Breysacher, G | 1 |
| Lagasse, JP | 1 |
| Di Fiore, F | 1 |
| Etienne, PL | 1 |
| Dupuis, OJM | 1 |
| Aleba, A | 1 |
| Lepage, C | 2 |
| Taieb, J | 1 |
| Lunenburg, CATC | 1 |
| Henricks, LM | 2 |
| Dreussi, E | 1 |
| Peters, FP | 1 |
| Fiocco, M | 1 |
| Meulendijks, D | 2 |
| Toffoli, G | 1 |
| Guchelaar, HJ | 2 |
| Swen, JJ | 1 |
| Cecchin, E | 1 |
| Schellens, JHM | 1 |
| Gelderblom, H | 1 |
| Chen, LT | 2 |
| Siveke, JT | 1 |
| Wang-Gillam, A | 1 |
| Li, CP | 1 |
| Bodoky, G | 1 |
| Dean, AP | 1 |
| Shan, YS | 1 |
| Jameson, GS | 1 |
| Macarulla, T | 1 |
| Lee, KH | 1 |
| Cunningham, D | 2 |
| Blanc, JF | 1 |
| Chiu, CF | 1 |
| Schwartsmann, G | 1 |
| Braiteh, FS | 1 |
| Mamlouk, K | 1 |
| Belanger, B | 1 |
| de Jong, FA | 1 |
| Hubner, RA | 1 |
| Yoshihiro, T | 1 |
| Kusaba, H | 1 |
| Makiyama, A | 1 |
| Kobayashi, K | 1 |
| Uenomachi, M | 1 |
| Ito, M | 1 |
| Doi, Y | 1 |
| Mitsugi, K | 1 |
| Aikawa, T | 1 |
| Takayoshi, K | 1 |
| Esaki, T | 1 |
| Shimokawa, H | 1 |
| Tsuchihashi, K | 1 |
| Ariyama, H | 1 |
| Akashi, K | 1 |
| Baba, E | 1 |
| Takii, Y | 1 |
| Maruyama, S | 1 |
| Hamza, S | 1 |
| Bouvier, AM | 1 |
| Rollot, F | 1 |
| Faivre, J | 1 |
| Bedenne, L | 3 |
| Kesavan, M | 1 |
| Claringbold, PG | 1 |
| Turner, JH | 1 |
| Perl, G | 1 |
| Ben-Aharon, I | 1 |
| Popovtzer, A | 1 |
| Stemmer, SM | 1 |
| Vidal, L | 1 |
| Ahlgren, J | 1 |
| Patel, N | 1 |
| Simmens, S | 1 |
| Akin, E | 1 |
| Bishop, C | 1 |
| Kirkel, D | 1 |
| Siegel, P | 1 |
| Schuck, S | 1 |
| Guebre-Xabiher, H | 1 |
| Siegel, R | 1 |
| Soveri, LM | 1 |
| Hermunen, K | 1 |
| de Gramont, A | 2 |
| Poussa, T | 1 |
| Quinaux, E | 2 |
| Bono, P | 1 |
| André, T | 2 |
| Österlund, P | 2 |
| Yang, TJ | 1 |
| Oh, JH | 1 |
| Apte, A | 1 |
| Son, CH | 1 |
| Deasy, JO | 1 |
| Goodman, KA | 1 |
| Zhang, WW | 1 |
| Zhu, YJ | 1 |
| Yang, H | 1 |
| Wang, QX | 1 |
| Wang, XH | 1 |
| Xiao, WW | 1 |
| Li, QQ | 1 |
| Liu, MZ | 1 |
| Hu, YH | 1 |
| Yeung, R | 1 |
| McConnell, Y | 1 |
| Warkentin, H | 1 |
| Graham, D | 1 |
| Warkentin, B | 1 |
| Joseph, K | 1 |
| Doll, CM | 1 |
| Aksinenko, SG | 1 |
| Suslov, NI | 1 |
| Povet'eva, TN | 1 |
| Nesterova, YV | 1 |
| Kharina, TG | 1 |
| Kravtsova, SS | 1 |
| Sonke, GS | 1 |
| Deenen, MJ | 1 |
| Froehlich, TK | 1 |
| Amstutz, U | 1 |
| Largiadèr, CR | 1 |
| Jennings, BA | 1 |
| Marinaki, AM | 1 |
| Sanderson, JD | 1 |
| Kleibl, Z | 2 |
| Kleiblova, P | 2 |
| Schwab, M | 1 |
| Zanger, UM | 1 |
| Palles, C | 1 |
| Tomlinson, I | 1 |
| Gross, E | 1 |
| van Kuilenburg, AB | 2 |
| Punt, CJ | 2 |
| Koopman, M | 1 |
| Beijnen, JH | 1 |
| Cats, A | 2 |
| Schellens, JH | 1 |
| Franco, P | 2 |
| Ragona, R | 2 |
| Arcadipane, F | 2 |
| Mistrangelo, M | 2 |
| Cassoni, P | 2 |
| Rondi, N | 2 |
| Morino, M | 2 |
| Racca, P | 2 |
| Ricardi, U | 2 |
| Chllamma, MK | 1 |
| Cook, N | 1 |
| Dhani, NC | 1 |
| Giby, K | 1 |
| Dodd, A | 1 |
| Wang, L | 1 |
| Hedley, DW | 1 |
| Moore, MJ | 1 |
| Knox, JJ | 1 |
| Martin-Romano, P | 1 |
| Sola, JJ | 1 |
| Diaz-Gonzalez, JA | 1 |
| Chopitea, A | 1 |
| Iragorri, Y | 1 |
| Martínez-Regueira, F | 1 |
| Ponz-Sarvise, M | 1 |
| Arbea, L | 1 |
| Subtil, JC | 1 |
| Cano, D | 1 |
| Ceniceros, L | 1 |
| Legaspi, J | 1 |
| Hernandez, JL | 1 |
| Rodríguez, J | 1 |
| Mahlberg, R | 1 |
| Lorenzen, S | 1 |
| Thuss-Patience, P | 1 |
| Heinemann, V | 1 |
| Pfeiffer, P | 1 |
| Möhler, M | 1 |
| Becerra, CR | 1 |
| Verma, UN | 1 |
| Tran, HT | 1 |
| Tavana, D | 1 |
| Williams, NS | 1 |
| Frenkel, EP | 1 |
| Liu, ZF | 1 |
| Guo, QS | 1 |
| Zhang, XQ | 1 |
| Yang, XG | 1 |
| Guan, F | 1 |
| Fu, Z | 1 |
| Wang, MY | 1 |
| Agostini, M | 1 |
| Pasetto, LM | 1 |
| Pucciarelli, S | 1 |
| Terrazzino, S | 1 |
| Ambrosi, A | 1 |
| Bedin, C | 1 |
| Galdi, F | 1 |
| Friso, ML | 1 |
| Mescoli, C | 1 |
| Urso, E | 1 |
| Leon, A | 1 |
| Lise, M | 1 |
| Nitti, D | 1 |
| Loibl, S | 1 |
| von Minckwitz, G | 1 |
| Harbeck, N | 1 |
| Janni, W | 1 |
| Elling, D | 1 |
| Kaufmann, M | 1 |
| Eggemann, H | 1 |
| Nekljudova, V | 1 |
| Sommer, H | 2 |
| Kiechle, M | 1 |
| Kümmel, S | 2 |
| Balduzzi, A | 1 |
| Montagna, E | 1 |
| Bagnardi, V | 1 |
| Torrisi, R | 1 |
| Bertolini, F | 1 |
| Mancuso, P | 1 |
| Scarano, E | 1 |
| Viale, G | 1 |
| Veronesi, P | 1 |
| Cardillo, A | 1 |
| Orlando, L | 1 |
| Goldhirsch, A | 1 |
| Colleoni, M | 1 |
| Ticha, I | 1 |
| Fidlerova, J | 1 |
| Novotny, J | 1 |
| Pohlreich, P | 1 |
| Degirmenci, M | 1 |
| Karaca, B | 1 |
| Gorumlu, G | 1 |
| Durusoy, R | 1 |
| Demir Piskin, G | 1 |
| Bozkurt, MT | 1 |
| Cirak, Y | 1 |
| Tunali, D | 1 |
| Karabulut, B | 1 |
| Sanli, UA | 1 |
| Uslu, R | 1 |
| Ozdemir, NY | 1 |
| Abali, H | 1 |
| Budakoglu, B | 1 |
| Uncu, D | 1 |
| Güler, T | 1 |
| Odabaşi, H | 1 |
| Zengin, N | 1 |
| Farhat, FS | 1 |
| Kattan, J | 1 |
| Chahine, GY | 1 |
| Younes, FC | 1 |
| Nasr, FL | 1 |
| Mroue, RM | 1 |
| Ghosn, MG | 1 |
| Cartwright, T | 1 |
| McCollum, D | 1 |
| Boehm, KA | 1 |
| Kachnic, LA | 1 |
| Tsai, HK | 1 |
| Coen, JJ | 1 |
| Blaszkowsky, LS | 1 |
| Hartshorn, K | 1 |
| Kwak, EL | 1 |
| Willins, JD | 1 |
| Ryan, DP | 1 |
| Hong, TS | 1 |
| Barhoumi, M | 1 |
| Mornex, F | 1 |
| Bonnetain, F | 2 |
| Rougier, P | 2 |
| Mariette, C | 1 |
| Bouché, O | 1 |
| Bosset, JF | 1 |
| Aparicio, T | 1 |
| Mineur, L | 1 |
| Azzedine, A | 1 |
| Hammel, P | 1 |
| Butel, J | 1 |
| Stremsdoerfer, N | 1 |
| Maingon, P | 1 |
| Chauffert, B | 1 |
| Hu, CY | 1 |
| Chan, W | 1 |
| Delclos, GP | 1 |
| Du, XL | 1 |
| Brixi-Benmansour, H | 1 |
| Jouve, JL | 1 |
| Mitry, E | 1 |
| Landi, B | 1 |
| Hentic, O | 1 |
| Cadiot, G | 1 |
| Palomo, AG | 1 |
| Glogowska, I | 1 |
| Malamos, N | 1 |
| Kilar, E | 1 |
| Vega, JM | 1 |
| Torrecillas, L | 1 |
| Delozier, T | 1 |
| Ettl, J | 1 |
| Finek, J | 1 |
| Zhong, LP | 1 |
| Zhang, CP | 1 |
| Ren, GX | 1 |
| Guo, W | 1 |
| William, WN | 1 |
| Sun, J | 1 |
| Zhu, HG | 1 |
| Tu, WY | 1 |
| Li, J | 2 |
| Cai, YL | 1 |
| Wang, LZ | 1 |
| Fan, XD | 1 |
| Wang, ZH | 1 |
| Hu, YJ | 1 |
| Ji, T | 1 |
| Yang, WJ | 1 |
| Ye, WM | 1 |
| He, Y | 1 |
| Wang, YA | 1 |
| Xu, LQ | 1 |
| Wang, BS | 1 |
| Kies, MS | 1 |
| Lee, JJ | 1 |
| Myers, JN | 1 |
| Zhang, ZY | 1 |
| Vulsteke, C | 1 |
| Lambrechts, D | 1 |
| Dieudonné, A | 1 |
| Hatse, S | 1 |
| Brouwers, B | 1 |
| van Brussel, T | 1 |
| Neven, P | 1 |
| Belmans, A | 1 |
| Schöffski, P | 1 |
| Paridaens, R | 1 |
| Wildiers, H | 1 |
| Hegewisch-Becker, S | 1 |
| Gruber, Y | 1 |
| Corovic, A | 1 |
| Pichlmeier, U | 1 |
| Atanackovic, D | 1 |
| Nierhaus, A | 1 |
| Hossfeld, DK | 1 |
| Nguyen, D | 1 |
| de la Rochefordière, A | 1 |
| Chauveinc, L | 1 |
| Cosset, JM | 1 |
| Clough, KB | 1 |
| Beuzeboc, P | 1 |
| Mouret-Fourme, E | 1 |
| Guyonnet, M | 1 |
| Leonard, RC | 1 |
| Twelves, C | 1 |
| Breddy, J | 1 |
| Chaturvedi, A | 1 |
| Hutcheon, A | 1 |
| Salazar, R | 1 |
| Cameron, D | 1 |
| Kohno, N | 1 |
| Kitahara, S | 1 |
| Tamura, E | 1 |
| Tanabe, T | 1 |
| Liu, TW | 1 |
| Wu, CW | 1 |
| Chung, TR | 1 |
| Shiah, HS | 1 |
| Jan, CM | 1 |
| Liu, JM | 1 |
| Whang-Peng, J | 1 |
| Chang, JY | 1 |
| Caponigro, F | 1 |
| Rosati, G | 1 |
| De Rosa, P | 1 |
| Avallone, A | 1 |
| De Rosa, V | 1 |
| De Lucia, L | 1 |
| Comella, P | 1 |
| Comella, G | 1 |
| Prost, P | 1 |
| Ychou, M | 1 |
| Azria, D | 1 |
| Besse, B | 1 |
| Spano, JP | 1 |
| Louvet, C | 1 |
| Carrat, F | 1 |
| Mal, F | 1 |
| Mabro, M | 1 |
| Beerblock, K | 1 |
| Vaillant, JC | 1 |
| Cady, J | 1 |
| Gamelin, E | 1 |
| Faul, C | 1 |
| Brufsky, A | 1 |
| Gerszten, K | 1 |
| Flickinger, J | 1 |
| Kunschner, A | 1 |
| Jacob, H | 1 |
| Vogel, V | 1 |
| Kojima, S | 1 |
| Takaba, K | 1 |
| Kimoto, N | 1 |
| Takeda, T | 1 |
| Kakuni, M | 1 |
| Mizutani, M | 1 |
| Suzuki, K | 1 |
| Sato, H | 1 |
| Hara, T | 1 |
| Boér, K | 1 |
| Láng, I | 1 |
| Juhos, E | 1 |
| Pintér, T | 1 |
| Szántó, J | 1 |
| Gourley, C | 1 |
| Cassidy, J | 1 |
| Edwards, C | 2 |
| Samuel, L | 1 |
| Bisset, D | 1 |
| Camboni, G | 1 |
| Young, A | 1 |
| Boyle, D | 1 |
| Jodrell, D | 1 |
| Ivanov, SD | 1 |
| Iamshanov, VA | 1 |
| Korytova, LI | 1 |
| Khazova, TV | 1 |
| Arzumanov, AS | 1 |
| Kuehr, T | 1 |
| Ruff, P | 1 |
| Rapoport, BL | 1 |
| Falk, S | 1 |
| Daniel, F | 1 |
| Jacobs, C | 1 |
| Davidson, N | 1 |
| Thaler, J | 1 |
| Boussard, B | 1 |
| Carmichael, J | 1 |
| Teufel, A | 1 |
| Steinmann, S | 1 |
| Siebler, J | 1 |
| Zanke, C | 1 |
| Hohl, H | 1 |
| Adami, B | 1 |
| Schroeder, M | 2 |
| Klein, O | 1 |
| Höhler, T | 1 |
| Galle, PR | 1 |
| Heike, M | 1 |
| Moehler, M | 1 |
| Oztop, I | 1 |
| Yilmaz, U | 1 |
| Yavuzsen, T | 1 |
| Yaren, A | 1 |
| Tarhan, O | 1 |
| Sagol, O | 1 |
| Coker, A | 1 |
| Alakavuklar, M | 1 |
| Saigi, E | 1 |
| Salut, A | 1 |
| Campos, JM | 1 |
| Losa, F | 1 |
| Manzano, H | 1 |
| Batiste-Alentorn, E | 1 |
| Acusa, A | 1 |
| Vélez de Mendizabal, E | 1 |
| Guasch, I | 1 |
| Antón, I | 1 |
| Rini, BI | 1 |
| Weinberg, V | 1 |
| Small, EJ | 1 |
| Erol, K | 1 |
| Baltali, E | 1 |
| Altundag, K | 1 |
| Guler, N | 1 |
| Ozisik, Y | 1 |
| Onat, DA | 1 |
| Sayek, I | 1 |
| Cengiz, M | 1 |
| Atahan, L | 1 |
| Tekuzman, G | 1 |
| De Maio, E | 2 |
| Gravina, A | 2 |
| Pacilio, C | 2 |
| Amabile, G | 1 |
| Labonia, V | 2 |
| Landi, G | 2 |
| Nuzzo, F | 2 |
| Rossi, E | 2 |
| D'Aiuto, G | 2 |
| Capasso, I | 1 |
| Rinaldo, M | 1 |
| Morrica, B | 1 |
| Elmo, M | 1 |
| Di Maio, M | 1 |
| Perrone, F | 2 |
| de Matteis, A | 2 |
| Stokes, Z | 1 |
| Symonds, P | 1 |
| Habeshaw, T | 1 |
| Reed, N | 1 |
| Curto, J | 1 |
| Joynson, C | 1 |
| Chan, S | 1 |
| Correale, P | 1 |
| Fulfaro, F | 1 |
| Marsili, S | 1 |
| Cicero, G | 1 |
| Bajardi, E | 1 |
| Intrivici, C | 1 |
| Vuolo, G | 1 |
| Carli, AF | 1 |
| Caraglia, M | 1 |
| Del Prete, S | 1 |
| Greco, E | 1 |
| Gebbia, N | 1 |
| Francini, G | 1 |
| Abdel-Wahab, M | 1 |
| Abitbol, A | 1 |
| Lewin, A | 1 |
| Troner, M | 1 |
| Hamilton, K | 1 |
| Markoe, A | 1 |
| Hurria, A | 2 |
| Brogan, K | 1 |
| Panageas, KS | 1 |
| Pearce, C | 1 |
| Norton, L | 3 |
| Jakubowski, A | 1 |
| Howard, J | 1 |
| Hudis, C | 2 |
| Saif, MW | 1 |
| Eloubeidi, MA | 1 |
| Russo, S | 2 |
| Steg, A | 1 |
| Thornton, J | 1 |
| Fiveash, J | 1 |
| Carpenter, M | 1 |
| Blanquicett, C | 1 |
| Diasio, RB | 1 |
| Johnson, MR | 1 |
| Martín, M | 1 |
| Lluch, A | 1 |
| Seguí, MA | 1 |
| Ruiz, A | 1 |
| Ramos, M | 1 |
| Adrover, E | 1 |
| Rodríguez-Lescure, A | 1 |
| Grosse, R | 1 |
| Calvo, L | 1 |
| Fernandez-Chacón, C | 1 |
| Roset, M | 1 |
| Antón, A | 1 |
| Isla, D | 1 |
| del Prado, PM | 1 |
| Iglesias, L | 1 |
| Zaluski, J | 1 |
| Arcusa, A | 1 |
| López-Vega, JM | 1 |
| Muñoz, M | 1 |
| Mel, JR | 1 |
| Klumpen, HJ | 1 |
| Westermann, AM | 1 |
| Zoetekouw, L | 1 |
| Van Lenthe, H | 1 |
| Bakker, PJ | 1 |
| Richel, DJ | 1 |
| Martoni, AA | 1 |
| Pinto, C | 1 |
| Di Fabio, F | 1 |
| Lelli, G | 1 |
| Rojas Llimpe, FL | 1 |
| Gentile, AL | 1 |
| Mutri, V | 1 |
| Ballardini, P | 1 |
| Giaquinta, S | 1 |
| Piana, E | 1 |
| Al-Batran, SE | 1 |
| Kerber, A | 1 |
| Atmaca, A | 1 |
| Dechow, C | 1 |
| Reitsamer, E | 1 |
| Schmidt, S | 1 |
| Kolassa, Y | 1 |
| Neumann, A | 1 |
| Weidmann, E | 1 |
| Hartmann, JT | 2 |
| Jäger, E | 1 |
| Kato, T | 1 |
| Mishima, H | 1 |
| Ikenaga, M | 1 |
| Murata, K | 1 |
| Ishida, H | 1 |
| Fukunaga, M | 1 |
| Ota, H | 1 |
| Tominaga, S | 1 |
| Ohnishi, T | 1 |
| Amano, M | 1 |
| Ikeda, K | 1 |
| Ikeda, M | 1 |
| Sekimoto, M | 1 |
| Sakamoto, J | 1 |
| Monden, M | 1 |
| Fine, RL | 1 |
| Fogelman, DR | 1 |
| Schreibman, SM | 1 |
| Desai, M | 1 |
| Sherman, W | 1 |
| Strauss, J | 1 |
| Guba, S | 1 |
| Andrade, R | 1 |
| Chabot, J | 1 |
| Bartsch, R | 1 |
| Wenzel, C | 1 |
| Altorjai, G | 1 |
| Pluschnig, U | 1 |
| Rudas, M | 1 |
| Mader, RM | 1 |
| Gnant, M | 1 |
| Zielinski, CC | 1 |
| Steger, GG | 1 |
| Amato, RJ | 1 |
| Khan, M | 1 |
| Jansen, EP | 1 |
| Boot, H | 1 |
| Dubbelman, R | 1 |
| Bartelink, H | 1 |
| Verheij, M | 1 |
| Kim, SG | 1 |
| Oh, SY | 1 |
| Kwon, HC | 1 |
| Lee, S | 1 |
| Kim, JH | 1 |
| Kim, SH | 1 |
| Kim, HJ | 1 |
| Im, CK | 1 |
| Jeung, HC | 1 |
| Rha, SY | 1 |
| Yoo, NC | 1 |
| Noh, SH | 1 |
| Roh, JK | 1 |
| Chung, HC | 1 |
| Fountzilas, G | 2 |
| Dafni, U | 1 |
| Gogas, H | 1 |
| Linardou, H | 1 |
| Kalofonos, HP | 1 |
| Briasoulis, E | 1 |
| Pectasides, D | 1 |
| Samantas, E | 1 |
| Bafaloukos, D | 1 |
| Stathopoulos, GP | 1 |
| Karina, M | 1 |
| Papadimitriou, C | 1 |
| Skarlos, D | 2 |
| Pisanidis, N | 1 |
| Papakostas, P | 2 |
| Markopoulos, C | 1 |
| Tzorakoeleftherakis, E | 1 |
| Dimitrakakis, K | 1 |
| Makrantonakis, P | 1 |
| Xiros, N | 1 |
| Polichronis, A | 1 |
| Varthalitis, I | 1 |
| Karanikiotis, C | 1 |
| Dimopoulos, AM | 1 |
| Takeuchi, S | 1 |
| Ohtsu, A | 1 |
| Doi, T | 1 |
| Kojima, T | 1 |
| Minashi, K | 1 |
| Mera, K | 1 |
| Yano, T | 1 |
| Tahara, M | 1 |
| Muto, M | 1 |
| Nihei, K | 1 |
| Morabito, A | 1 |
| Di Rella, F | 1 |
| Piccirillo, MC | 1 |
| Thomas, R | 1 |
| Gori, S | 1 |
| Colozza, M | 1 |
| De Placido, S | 1 |
| Lauria, R | 1 |
| Signoriello, G | 1 |
| Gallo, C | 1 |
| Schmid, P | 1 |
| Kühnhardt, D | 1 |
| Kiewe, P | 1 |
| Lehenbauer-Dehm, S | 1 |
| Schippinger, W | 1 |
| Greil, R | 1 |
| Lange, W | 1 |
| Preiss, J | 1 |
| Niederle, N | 1 |
| Brossart, P | 1 |
| Freier, W | 1 |
| Van de Velde, H | 1 |
| Regierer, A | 1 |
| Possinger, K | 1 |
| François, E | 1 |
| Berdah, JF | 1 |
| Chamorey, E | 1 |
| Lesbats, G | 1 |
| Teissier, E | 1 |
| Codoul, JF | 1 |
| Badetti, JL | 1 |
| Hébert, C | 1 |
| Mari, V | 1 |
| Lim, JY | 1 |
| Cho, JY | 1 |
| Paik, YH | 1 |
| Lee, DK | 1 |
| Lee, SI | 1 |
| Park, HJ | 1 |
| Lee, SJ | 1 |
| Lee, KS | 1 |
| Yoon, DS | 1 |
| Choi, SH | 1 |
| Di Costanzo, F | 4 |
| Gasperoni, S | 1 |
| Manzione, L | 1 |
| Bisagni, G | 1 |
| Labianca, R | 1 |
| Bravi, S | 1 |
| Cortesi, E | 1 |
| Carlini, P | 1 |
| Bracci, R | 1 |
| Tomao, S | 1 |
| Messerini, L | 1 |
| Arcangeli, A | 1 |
| Torri, V | 1 |
| Bilancia, D | 1 |
| Floriani, I | 1 |
| Tonato, M | 2 |
| Dinota, A | 1 |
| Strafiuso, G | 1 |
| Corgna, E | 1 |
| Porrozzi, S | 1 |
| Boni, C | 1 |
| Rondini, E | 1 |
| Giunta, A | 1 |
| Monzio Compagnoni, B | 1 |
| Biagioni, F | 1 |
| Cesari, M | 1 |
| Fornarini, G | 1 |
| Nelli, F | 1 |
| Carboni, M | 1 |
| Cognetti, F | 1 |
| Enzo, MR | 1 |
| Piga, A | 1 |
| Romiti, A | 1 |
| Olivetti, A | 1 |
| Masoni, L | 1 |
| De Stefanis, M | 1 |
| Dalla Mola, A | 1 |
| Camera, S | 1 |
| Recchia, F | 1 |
| De Filippis, S | 1 |
| Scipioni, L | 1 |
| Zironi, S | 1 |
| Luppi, G | 1 |
| Italia, M | 1 |
| Banducci, S | 1 |
| Pisani Leretti, A | 1 |
| Massidda, B | 1 |
| Ionta, MT | 1 |
| Nicolosi, A | 1 |
| Canaletti, R | 1 |
| Biscottini, B | 1 |
| Grigniani, F | 1 |
| Rovei, R | 1 |
| Croce, E | 1 |
| Carroccio, R | 1 |
| Gilli, G | 1 |
| Cavalli, C | 1 |
| Olgiati, A | 1 |
| Pandolfi, U | 1 |
| Rossetti, R | 1 |
| Natalini, G | 1 |
| Foa, P | 1 |
| Oldani, S | 1 |
| Bruno, L | 1 |
| Cascinu, S | 1 |
| Catalano, G | 1 |
| Catalano, V | 1 |
| Lungarotti, F | 1 |
| Farris, A | 1 |
| Sarobba, MG | 1 |
| Trignano, M | 1 |
| Muscogiuri, A | 1 |
| Francavilla, F | 1 |
| Figoli, F | 1 |
| Leoni, M | 1 |
| Papiani, G | 1 |
| Orselli, G | 1 |
| Antimi, M | 1 |
| Bellini, V | 1 |
| Cabassi, A | 1 |
| Contu, A | 1 |
| Pazzola, A | 1 |
| Frignano, M | 1 |
| Lastraioli, E | 1 |
| Saggese, M | 1 |
| Bianchini, D | 1 |
| Antonuzzo, L | 1 |
| Mela, M | 1 |
| Camisa, R | 1 |
| Chang, PM | 1 |
| Chen, PM | 1 |
| Chu, PY | 1 |
| Wang, LW | 1 |
| Tai, SK | 1 |
| Tsai, TL | 1 |
| Huang, JL | 1 |
| Wang, YF | 1 |
| Chang, SY | 1 |
| Yang, MH | 1 |
| Traina, TA | 1 |
| Theodoulou, M | 1 |
| Feigin, K | 1 |
| Patil, S | 1 |
| Tan, KL | 1 |
| Dugan, U | 1 |
| Gruenberger, B | 1 |
| Tamandl, D | 1 |
| Schueller, J | 1 |
| Scheithauer, W | 1 |
| Zielinski, C | 1 |
| Herbst, F | 1 |
| Gruenberger, T | 1 |
| Puglisi, F | 1 |
| Cardellino, GG | 1 |
| Crivellari, D | 1 |
| Di Loreto, C | 1 |
| Magri, MD | 1 |
| Minisini, AM | 1 |
| Mansutti, M | 1 |
| Andreetta, C | 1 |
| Lombardi, D | 1 |
| Perin, T | 1 |
| Damante, G | 1 |
| Veronesi, A | 1 |
| Higgins, GA | 2 |
| Donaldson, RC | 1 |
| Rogers, LS | 1 |
| Juler, GL | 1 |
| Keehn, RJ | 2 |
| Bukowski, RM | 2 |
| Balcerzak, SP | 1 |
| O'Bryan, RM | 1 |
| Bonnet, JD | 1 |
| Chen, TT | 2 |
| Cunningham, J | 1 |
| Budd, GT | 1 |
| Weick, JK | 1 |
| Purvis, J | 1 |
| Pitman, SW | 1 |
| Kowal, CD | 1 |
| Bertino, JR | 1 |
| Begg, CB | 1 |
| Carbone, PP | 3 |
| Amadeo, JH | 1 |
| McElhinney, J | 1 |
| McCaughan, JJ | 1 |
| Engstrom, PF | 2 |
| MacIntyre, JM | 1 |
| Mittelman, A | 1 |
| Klaassen, DJ | 1 |
| Panettiere, FJ | 1 |
| Haas, C | 1 |
| McDonald, B | 1 |
| Costanzi, JJ | 1 |
| Talley, RW | 1 |
| Athens, J | 1 |
| Oishi, N | 1 |
| Heilbrun, LK | 1 |
| Fox, RM | 1 |
| Woods, RL | 1 |
| Tattersall, MH | 1 |
| Piper, AA | 1 |
| Sampson, D | 1 |
| Cadman, EC | 1 |
| Glick, JH | 1 |
| Cross, J | 1 |
| Horton, J | 1 |
| Taylor, SG | 2 |
| Israel, L | 1 |
| Breau, JL | 1 |
| Aguilera, J | 1 |
| Lawson, DH | 1 |
| Nixon, DW | 1 |
| Kutner, MH | 1 |
| Heymsfield, SB | 1 |
| Rudman, D | 1 |
| Moffitt, S | 1 |
| Ansley, J | 1 |
| Chawla, R | 1 |
| Ajani, JA | 1 |
| Ilson, DH | 2 |
| Kelsen, DP | 3 |
| Van Hoef, ME | 1 |
| Baumann, I | 1 |
| Lange, C | 1 |
| Luft, T | 1 |
| de Wynter, EA | 1 |
| Ranson, M | 1 |
| Morgenstern, GR | 1 |
| Yvers, A | 1 |
| Dexter, TM | 1 |
| Testa, NG | 1 |
| Del Mastro, L | 1 |
| Garrone, O | 1 |
| Sertoli, MR | 1 |
| Canavese, G | 1 |
| Catturich, A | 1 |
| Guenzi, M | 1 |
| Rosso, R | 2 |
| Venturini, M | 1 |
| Chi, KH | 1 |
| Chen, CH | 1 |
| Chan, WK | 1 |
| Chow, KC | 1 |
| Chen, SY | 1 |
| Yen, SH | 1 |
| Chao, JY | 1 |
| Chang, CY | 1 |
| Chen, KY | 1 |
| Sirott, M | 1 |
| Saltz, L | 2 |
| Heelan, R | 1 |
| Huang, Y | 1 |
| Keresztes, R | 1 |
| Frasci, G | 1 |
| Leone, F | 1 |
| Monaco, M | 1 |
| Cremone, L | 1 |
| Sapio, U | 1 |
| Faiella, F | 1 |
| Espinosa, A | 1 |
| Persico, G | 1 |
| Chevallier, B | 2 |
| Roche, H | 2 |
| Olivier, JP | 1 |
| Chollet, P | 1 |
| Hurteloup, P | 1 |
| Cvitkovic, FB | 1 |
| Haie-Meder, C | 1 |
| Papadimitrakopoulou, V | 1 |
| Armand, JP | 2 |
| Cioloca, C | 1 |
| Maugis, N | 1 |
| Constans, JP | 1 |
| Atiq, OT | 1 |
| Shiu, MH | 1 |
| Tong, W | 1 |
| Niedzwiecki, D | 1 |
| Trochanowski, B | 1 |
| Lin, S | 1 |
| Toomasi, F | 1 |
| Brennan, M | 1 |
| Ryffel, B | 1 |
| Mihatsch, MJ | 1 |
| Woerly, G | 1 |
| Coombes, RC | 1 |
| Bliss, JM | 1 |
| Wils, J | 2 |
| Morvan, F | 1 |
| Espié, M | 1 |
| Amadori, D | 1 |
| Gambrosier, P | 1 |
| Richards, M | 1 |
| Aapro, M | 1 |
| Villar-Grimalt, A | 1 |
| McArdle, C | 1 |
| Pérez-López, FR | 1 |
| Vassilopoulos, P | 1 |
| Ferreira, EP | 1 |
| Chilvers, CE | 1 |
| Coombes, G | 1 |
| Woods, EM | 1 |
| Marty, M | 1 |
| Lokich, J | 2 |
| Anderson, N | 1 |
| Moore, C | 1 |
| Bern, M | 1 |
| Coco, F | 1 |
| Dow, E | 1 |
| Zipoli, T | 1 |
| Gonzalves, L | 1 |
| Au, E | 1 |
| Koo, WH | 1 |
| Tan, EH | 1 |
| Ang, PT | 1 |
| Bergh, J | 1 |
| Wiklund, T | 1 |
| Erikstein, B | 1 |
| Fornander, T | 1 |
| Bengtsson, NO | 1 |
| Malmström, P | 1 |
| Kellokumpu-Lehtinen, P | 1 |
| Anker, G | 1 |
| Bennmarker, H | 1 |
| Wilking, N | 1 |
| Lévy, E | 1 |
| Piedbois, P | 1 |
| Buyse, M | 1 |
| Pignon, JP | 1 |
| Ryan, L | 1 |
| Hansen, R | 1 |
| Zee, B | 1 |
| Weinerman, B | 1 |
| Pater, J | 1 |
| Leichman, C | 1 |
| Macdonald, J | 1 |
| Benedetti, J | 1 |
| Fryer, J | 1 |
| Brufman, G | 1 |
| Isacson, R | 1 |
| Laplanche, A | 1 |
| Thirion, P | 1 |
| Uchida, N | 1 |
| Takeda, Y | 1 |
| Hojo, K | 1 |
| Maekawa, R | 1 |
| Sugita, K | 1 |
| Yoshioka, T | 1 |
| Zalcberg, J | 1 |
| Kerr, D | 1 |
| Seymour, L | 1 |
| Palmer, M | 1 |
| Van Cutsem, E | 1 |
| Ten Bokkel Huinink, WW | 1 |
| Alexopoulos, CG | 1 |
| Dirix, L | 1 |
| Symann, M | 1 |
| Blijham, GH | 1 |
| Cholet, P | 1 |
| Fillet, G | 1 |
| Van Groeningen, C | 1 |
| Vannetzel, JM | 1 |
| Levi, F | 1 |
| Panagos, G | 1 |
| Unger, C | 1 |
| Cote, C | 1 |
| Blanc, C | 1 |
| Hérait, P | 2 |
| Bleiberg, H | 1 |
| Kasseyet, S | 1 |
| Astoul, P | 1 |
| Boutin, C | 1 |
| Hasbini, A | 1 |
| Mahjoubi, R | 1 |
| Fandi, A | 1 |
| Chouaki, N | 1 |
| Taamma, A | 1 |
| Lianes, P | 1 |
| Cortès-Funes, H | 1 |
| Alonso, S | 1 |
| Cvitkovic, E | 2 |
| Raymond, E | 1 |
| Hidalgo, M | 1 |
| Villalona-Calero, MA | 1 |
| Eckhardt, SG | 1 |
| Drengler, RL | 1 |
| Rodriguez, G | 1 |
| Hammond, LA | 1 |
| Diab, SG | 1 |
| Weiss, G | 1 |
| Garner, AM | 1 |
| Campbell, E | 1 |
| Davidson, K | 1 |
| Louie, A | 1 |
| O'Neil, JD | 1 |
| von Borstel, R | 1 |
| Von Hoff, DD | 1 |
| Rowinsky, EK | 1 |
| Janinis, J | 1 |
| Samelis, G | 1 |
| Papagianopoulos, P | 1 |
| Kucuk, O | 1 |
| Shevrin, DH | 1 |
| Pandya, KJ | 1 |
| Bonomi, PD | 1 |
| Park, TK | 1 |
| Kim, SN | 1 |
| Kim, SW | 1 |
| Kim, GE | 1 |
| Suh, CO | 1 |
| Goldwasser, F | 1 |
| Gross-Goupil, M | 1 |
| Tigaud, JM | 1 |
| Di Palma, M | 1 |
| Marceau-Suissa, J | 1 |
| Wasserman, E | 1 |
| Yovine, A | 1 |
| Misset, JL | 1 |
| Chen, JS | 1 |
| Lin, YC | 1 |
| Jan, YY | 1 |
| Liau, CT | 1 |
| Szatkowska, L | 1 |
| Mazurkiewicz, M | 1 |
| Brzozowska, A | 1 |
| Elomaa, I | 1 |
| Virkkunen, P | 1 |
| Joensuu, H | 1 |
| Stockeld, D | 1 |
| Tennvall, J | 1 |
| Wagenius, G | 1 |
| Albertsson, M | 1 |
| Backman, L | 1 |
| Brodin, O | 1 |
| Cwikiel, M | 1 |
| Granström, L | 1 |
| Gustafsson, G | 1 |
| Gustavsson, S | 1 |
| Hambraeus, G | 1 |
| Lewensohn, R | 1 |
| Sjöstedt, S | 1 |
| Strander, H | 1 |
| Aberg, B | 1 |
| Fagerberg, J | 1 |
| Winer, EP | 1 |
| Burstein, HJ | 1 |
| Patt, YZ | 1 |
| Hassan, MM | 1 |
| Lozano, RD | 1 |
| Waugh, KA | 1 |
| Hoque, AM | 1 |
| Frome, AI | 1 |
| Lahoti, S | 1 |
| Ellis, L | 1 |
| Vauthey, JN | 1 |
| Curley, SA | 1 |
| Schnirer, II | 1 |
| Raijman, I | 1 |
| Honecker, F | 1 |
| Kollmannsberger, C | 1 |
| Quietzsch, D | 1 |
| Haag, C | 1 |
| Spott, C | 1 |
| Baronius, W | 1 |
| Hempel, V | 1 |
| Kanz, L | 1 |
| Bokemeyer, C | 1 |
| Schmidt, JD | 1 |
| Beex, LV | 1 |
| Hermus, AR | 1 |
| Pieters, GF | 1 |
| van Hoesel, QG | 1 |
| Nooy, MA | 1 |
| Mignolet, F | 1 |
| Dawson, NA | 1 |
| Costanza, ME | 1 |
| Korzun, AH | 1 |
| Clamon, GH | 1 |
| Pollak, M | 1 |
| Vogelzang, NJ | 1 |
| Carey, RW | 1 |
| Ransom, DT | 1 |
| Neuberg, D | 1 |
| Loprinzi, CL | 1 |
| Tormey, DC | 4 |
| Blum, RH | 1 |
| Harris, JE | 1 |
| Asbury, RF | 1 |
| Falkson, G | 3 |
| Lichtman, SM | 1 |
| Budman, D | 1 |
| Bosworth, H | 1 |
| Allen, S | 1 |
| Schulman, P | 1 |
| Weiselberg, L | 1 |
| Weiss, R | 1 |
| Lehrman, D | 1 |
| Vinciguerra, V | 1 |
| Saphner, T | 1 |
| Albertini, M | 1 |
| Fumoleau, P | 1 |
| Kerbrat, P | 1 |
| Monnier, A | 1 |
| Goudie, MJ | 1 |
| Hortobagyi, GN | 1 |
| Theriault, RL | 1 |
| Frye, D | 1 |
| Walters, RS | 1 |
| Fraschini, G | 1 |
| Tashima, CK | 1 |
| Ro, JS | 1 |
| Salewski, E | 1 |
| Buzdar, AU | 1 |
| Green, DM | 1 |
| Krischer, JP | 1 |
| Bell, B | 1 |
| Brecher, ML | 1 |
| Cushing, B | 1 |
| Whitehead, VM | 1 |
| Cullinan, SA | 1 |
| Moertel, CG | 2 |
| Fleming, TR | 1 |
| Rubin, JR | 1 |
| Krook, JE | 1 |
| Everson, LK | 1 |
| Windschitl, HE | 1 |
| Twito, DI | 1 |
| Marschke, RF | 1 |
| Foley, JF | 1 |
| Lindeløv, B | 1 |
| Hansen, HS | 1 |
| Jabboury, K | 1 |
| Holmes, FA | 1 |
| Hortobagyi, G | 1 |
| Nadal, JC | 1 |
| van Groeningen, CJ | 1 |
| Pinedo, HM | 1 |
| Peters, GJ | 1 |
| Bartolucci, R | 1 |
| Padalino, D | 1 |
| Brugia, M | 1 |
| Buzzi, F | 1 |
| Schnitzler, G | 1 |
| Queisser, W | 1 |
| Heim, ME | 1 |
| König, H | 1 |
| Katz, R | 1 |
| Fritze, D | 1 |
| Herrmann, R | 1 |
| Arnold, H | 1 |
| Henss, H | 1 |
| Trux, FA | 1 |
| De Lisi, V | 1 |
| Cocconi, G | 1 |
| Leonardi, F | 1 |
| Soldani, M | 1 |
| Forastiere, AA | 1 |
| Natale, RB | 1 |
| Takasugi, BJ | 1 |
| Goren, MP | 1 |
| Vogel, WC | 1 |
| Kudla-Hatch, V | 1 |
| Livingston, RB | 1 |
| Schulman, S | 1 |
| Griffin, BR | 1 |
| Tranum, BL | 1 |
| Rivkin, SE | 1 |
| Goldberg, RS | 1 |
| Fabian, CJ | 1 |
| Hammond, N | 1 |
| Hynes, H | 1 |
| Garewal, H | 1 |
| Ahmann, FR | 1 |
| Adelstein, DJ | 1 |
| Sharan, VM | 1 |
| Earle, AS | 1 |
| Shah, AC | 1 |
| Vlastou, C | 1 |
| Haria, CD | 1 |
| Carter, SG | 1 |
| Damm, C | 1 |
| Hines, JD | 1 |
| Muggia, FM | 1 |
| Camacho, FJ | 1 |
| Kaplan, BH | 1 |
| Green, MD | 1 |
| Greenwald, ES | 1 |
| Wernz, JC | 1 |
| Gelman, RS | 1 |
| Cummings, FJ | 1 |
| Falkson, HC | 1 |
| Kalish, LA | 1 |
| Olson, JE | 1 |
| Cummings, F | 1 |
| Bennett, JM | 1 |
| Sugarbaker, PH | 1 |
| Gianola, FJ | 1 |
| Speyer, JL | 1 |
| Wesley, R | 1 |
| Barofsky, I | 1 |
| Myers, CE | 1 |
| Merlano, M | 1 |
| Tatarek, R | 1 |
| Grimaldi, A | 1 |
| Margarino, G | 1 |
| Loehrer, PJ | 1 |
| Einhorn, LH | 1 |
| Williams, SD | 1 |
| Hui, SL | 1 |
| Estes, NC | 1 |
| Pennington, K | 1 |
| Huys, J | 1 |
| Van Vaerenbergh, PM | 1 |
| Pivniuk, VM | 1 |
| Buklina, ZP | 1 |
| Ezerskaia, LIa | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II: First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis[NCT01674309] | Phase 2 | 65 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy[NCT01494506] | Phase 3 | 417 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| Phase II Trial of Weekly Carboplatin-Paclitaxel Adjuvant Chemotherapy After Intensity Modulated Extended-field Chemoradiation in the Treatment of Locally Advanced Cervical Cancer With Para-aortic Positive Nodes[NCT04016142] | Phase 2 | 21 participants (Actual) | Interventional | 2020-07-15 | Active, not recruiting | ||
| Study of First-Line Therapy Comprising Leucovorin Calcium, Fluorouracil, and Irinotecan (FOLFIRI) in Patients With Progressive Locally Advanced or Metastatic Duodenal-Pancreatic Endocrine Tumors[NCT00416767] | Phase 2 | 20 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| A Prospective, Single-arm, Phase II Study of Adelbelimab Combined With Carboplatin and Nab-paclitaxel in Neoadjuvant Therapy for Patients With Resectable Locally Advanced Squamous Cell Carcinoma of the Head and Neck[NCT06016413] | Phase 2 | 30 participants (Anticipated) | Interventional | 2023-09-01 | Not yet recruiting | ||
| Study of TPF (Docetaxel, Cisplatin, 5-fluorouracil) Induction Chemotherapy Followed by Surgery and Radiotherapy in Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma[NCT01542931] | Phase 2/Phase 3 | 256 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Intermittent Every Other Days of 5 Shot-filgrastim Compared With Single Pegfilgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide Chemotherapy (Intermittent G-CSF 105)[NCT02685111] | Phase 2 | 22 participants (Actual) | Interventional | 2016-02-29 | Terminated | ||
| Multicentre Randomized Phase II Study of Neoadjuvant Trastuzumab Plus Docetaxel With and Without Bevacizumab and Trastuzumab Plus Docetaxel Plus Non-pegylated Liposome-encapsulated Doxorubicin (NPLD) With and Without Bevacizumab in HER2-positive Early Bre[NCT01367028] | Phase 2 | 100 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Adjuvant Chemotherapy in Elderly Patients With Breast Cancer: Weekly Docetaxel vs. CMF[NCT00331097] | Phase 3 | 300 participants (Actual) | Interventional | 2003-07-31 | Completed | ||
| A Phase II Study of Docetaxel and Epirubicin Combination in Patients With Advanced Gastric Cancer.[NCT00375999] | Phase 2 | 34 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| Randomized Phase 2 Study Comparing Pathological Responses on Colorectal Cancer Metastases After Preoperative Treatment Combining Bevacizumab With FOLFOX or FOLFIRI[NCT01858649] | Phase 2 | 60 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| Randomised Phase 2 Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors[NCT01858662] | Phase 2 | 4 participants (Actual) | Interventional | 2014-01-31 | Terminated (stopped due to due to poor recrutment) | ||
| Exploration of New Biologic Factors' Predictive Value , Especially Circulating VE-cadherin in Metastatic Colorectal Adenocarcinoma Patients Treated With Bevacizumab[NCT01405430] | 63 participants (Actual) | Interventional | 2010-05-31 | Completed | |||
| The Optimisation of 5-Fluorouracil Dose by Pharmacokinetic Monitoring in Asian Patients With Advanced Stage Cancer[NCT00943137] | Phase 2 | 55 participants (Anticipated) | Interventional | 2009-06-30 | Active, not recruiting | ||
| Phase Ⅱ Clinical Study of RALOX or CAPOX Combined With Bevacizumab in the First-line Treatment of Advanced Colorectal Cancer[NCT03813641] | Phase 2 | 100 participants (Anticipated) | Interventional | 2019-01-28 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The objective response rate was a secondary efficacy endpoint of the study and was defined by the percentage of patients in the study population with a best overall response of Complete Response (CR) or Partial Response (PR) as assessed by the investigator. Best overall response was defined per RECIST (version 1.1) recorded from randomization until progression or end of study. RECIST (v 1.1) criteria does not require confirmation of response, but an additional, more stringent analysis was also conducted, with designation of CR (or PR) requiring confirmation of response at least 4 weeks following the initial assessment of CR (or PR). Stable disease (SD) required an assessment of SD at least 6 weeks after starting treatment. Subjects with insufficient data for response classification were classified as Not Evaluable for best overall response, and as a non-responder for objective response, in the ITT population. Treatment groups are as indicated for the primary outcome of OS. (NCT01494506)
Timeframe: Assessment every 6 weeks after initial response; Day 1 to data cut off of 14 Feb 2014; maximum time on study 25 months.
| Intervention | percentage with confirmed response (Number) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 3.31 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 0.67 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 7.69 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 0.84 |
"Overall survival was the primary efficacy endpoint of the study and was defined as the time from the date of patient randomization to the date of death or the date the patient was last known to be alive. OS was summarized by Kaplan-Meier methodology for each treatment group. Pairwise treatment group comparisons were carried out using unstratified log rank analyses on the ITT population. Hazard ratio estimates are from Cox regression analysis.~The comparison of Arm C is based only on patients who were randomized under the 3-arm version of the protocol. Consequently, the 5-FU+Leucovorin (Combo Therapy Comparison) group is a subset of all patients randomized to 5-FU+Leucovorin, which is the Mono Therapy Comparison control and contains patients randomized under both the 2-arm and 3-arm versions of the protocol." (NCT01494506)
Timeframe: From randomization to death; until the data cut off 14 Feb 2014. The maximum time in follow up was 25 months.
| Intervention | months (Median) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 4.9 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 4.2 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 6.1 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 4.2 |
"Composite measure based on patient-reported pain (per VAS), patient-reported pain medication, KPS, and weight. Clinical benefit is indicated by either:~(a) improvement in pain (less pain intensity with stable or decreased pain medication; or less pain medication with stable or decreased pain intensity) with stable or improved KPS; or (b) improvement in KPS with stable or improved pain.~With stable for KPS and pain, clinical benefit may be indicated with an observation of positive weight change.~Clinical benefit response (CBR) was classified weekly and a patient was considered a clinical benefit responder if clinical benefit was observed and maintained over a 4 week period." (NCT01494506)
Timeframe: Randomization to treatment discontinuation.The maximum time in follow up was 25 months
| Intervention | percentage of participants with CBR (Number) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 14 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 13 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 14 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 12 |
Tumor marker response (TMR) was evaluated by the change in CA19-9 serum levels. Response was defined as a decrease of 50% of CA19-9 in relation to the baseline level at least once during the treatment period. (NCT01494506)
Timeframe: Baseline to treatment discontinuation every 6 weeks; The maximum time in follow up was 25 months
| Intervention | percent of participants with TMR (Number) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 23.6 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 11.4 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 28.9 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 8.6 |
"Progression-free survival was defined as the time from the date of randomization to the date of disease progression, or death (any cause) on or prior to the clinical cutoff date, whichever occurred earlier. Participants who did not have disease progression or had not died were censored at the date of the last tumor assessment. Patients with two or more consecutive missing response assessments prior to a visit with documented progression (or death) were censored at the last date of tumor assessment when the patient was documented to be progression free. PFS was summarized using Kaplan-Meier methods.~The comparison of Arm C is based only on patients who were randomized under the 3-arm version of the protocol. Consequently, the 5-FU+Leucovorin (Combo Therapy Comparison) group is a subset of all patients randomized to 5-FU+Leucovorin, which is the Mono Therapy Comparison control and contains patients randomized under both the 2-arm and 3-arm versions of the protocol." (NCT01494506)
Timeframe: Randomization until disease progression or death from any cause; Until the data cut off of 14 Feb 2014. The maximum time in follow up was 25 months.
| Intervention | months (Median) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 2.7 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 1.6 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 3.1 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 1.5 |
Time from randomization to discontinuation of treatment for any reason, including disease progression, treatment toxicity or death. (NCT01494506)
Timeframe: Randomization to treatment discontinuation (any cause). The maximum time in follow up was 25 months
| Intervention | months (Median) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 1.7 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 1.4 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 2.3 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 1.4 |
This patient recorded outcome consists of 15 subscales in 3 independent domains: global health-related quality of life (HRQoL), functional scales (cognitive, emotional, physical, role and social functioning), and symptom scales (appetite loss, constipation, diarrhea, dyspnea, fatigue, insomnia, nausea and vomiting, and pain). For each subscale, patients were classified as improved, worsened or stable. Improvement is indicated by achievement of subscale score at least 10% improved from baseline and maintained for at least 6 weeks. Worsened is indicated by subscale score at least 10% worse than baseline. Stable is indicated by neither improvement nor worsened. Achievement of improvement prior to worsening was classified as improvement. (NCT01494506)
Timeframe: Baseline to treatment discontinuation every 6 weeks; The maximum time in follow up was 25 months
| Intervention | percent of patients in category (Number) | ||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global Health Status: Improved | Global Health Status: Stable | Global Health Status: Worsened | Physical Functioning: Improved | Physical Functioning: Stable | Physical Functioning: Worsened | Role Functioning: Improved | Role Functioning: Stable | Role Functioning: Worsened | Emotional Functioning:Improved | Emotional Functioning:Stable | Emotional Functioning:Worsened | Cognitive Functioning:Improved | Cognitive Functioning:Stable | Cognitive Functioning:Worsened | Social Functioning:Improved | Social Functioning:Stable | Social Functioning:Worsened | Fatigue:Improved | Fatigue:Stable | Fatigue:Worsened | Nausea and Vomiting:Improved | Nausea and Vomiting:Stable | Nausea and Vomiting:Worsened | Pain:Improved | Pain:Stable | Pain:Worsened | Dyspnoea:Improved | Dyspnoea:Stable | Dyspnoea:Worsoned | Insomnia:Improved | Insomnia:Stable | Insomnia:Worsened | Appetite Loss:Improved | Appetite Loss:Stable | Appetite Loss:Worsened | Constipation:Improved | Constipation:Stable | Constipation:Worsened | Diarrhoea:Improved | Diarrhoea: Stable | Diarrhoea: Worsened | Financial Difficulties: Improved | Financial Difficulties: Stable | Financial Difficulties: Worsened | |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 11 | 41 | 48 | 11 | 37 | 52 | 10 | 39 | 52 | 8 | 59 | 33 | 6 | 42 | 52 | 11 | 43 | 46 | 11 | 30 | 59 | 6 | 42 | 52 | 10 | 37 | 53 | 6 | 69 | 24 | 4 | 49 | 47 | 6 | 42 | 52 | 4 | 63 | 34 | 4 | 58 | 39 | 1 | 67 | 31 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 12 | 44 | 44 | 11 | 40 | 49 | 11 | 37 | 53 | 9 | 58 | 33 | 7 | 44 | 49 | 11 | 47 | 42 | 12 | 33 | 54 | 4 | 46 | 51 | 11 | 40 | 49 | 5 | 68 | 25 | 5 | 49 | 46 | 5 | 46 | 49 | 4 | 67 | 30 | 4 | 58 | 39 | 0 | 74 | 26 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 17 | 38 | 45 | 10 | 41 | 49 | 15 | 32 | 52 | 20 | 46 | 34 | 11 | 48 | 41 | 13 | 34 | 54 | 14 | 20 | 66 | 13 | 32 | 55 | 27 | 34 | 39 | 7 | 51 | 42 | 18 | 34 | 48 | 11 | 45 | 44 | 13 | 56 | 31 | 6 | 39 | 55 | 8 | 51 | 41 |
| MM-398 Arm A (Mono Therapy Comparison) | 10 | 31 | 57 | 10 | 29 | 61 | 6 | 29 | 66 | 10 | 32 | 56 | 12 | 32 | 54 | 11 | 26 | 62 | 13 | 18 | 69 | 5 | 37 | 58 | 20 | 30 | 50 | 10 | 47 | 44 | 9 | 43 | 48 | 9 | 38 | 53 | 13 | 47 | 39 | 4 | 35 | 59 | 6 | 51 | 42 |
Plasma concentration-time data for MM-398 will be analyzed using population pharmacokinetic methods. (NCT01494506)
Timeframe: 6 weeks after first study drug administration
| Intervention | Total irinotecan = ug/L; SN38= ug/L (Geometric Mean) | |||
|---|---|---|---|---|
| Total Irinotecan-Cavg | Total Irinotecan-Cmax | Total SN38-Cavg | Total SN38-Cmax | |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 2120.00 | 28460.00 | 0.68 | 2.58 |
| MM-398 Arm A (Mono Therapy Comparison) | 2550.00 | 40550.00 | 0.82 | 3.93 |
(NCT00375999)
Timeframe: One year
| Intervention | month (Median) |
|---|---|
| Treatment Group | 13.4 |
12 reviews available for fluorouracil and Blood Diseases
| Article | Year |
|---|---|
Addition of taxane to induction therapy in head and neck malignancies: a systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Databases, Factual; Disease-Free Survival; Female; Fl | 2013 |
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gas | 2015 |
New Perspectives in the Treatment of Advanced Gastric Cancer: S-1 as a Novel Oral 5-FU Therapy in Combination with Cisplatin.
Topics: Administration, Oral; Antineoplastic Agents; Cisplatin; Drug Therapy, Combination; Fluorouracil; Hem | 2017 |
Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; | 2008 |
Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Ant | 2010 |
Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2010 |
[Gemcitabine and pancreatic cancer].
Topics: Adenocarcinoma; Analgesia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pro | 2002 |
[Gemcitabine and breast cancer].
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetaboli | 2002 |
A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2008 |
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.
Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Huma | 1998 |
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.
Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Huma | 1998 |
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.
Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Huma | 1998 |
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.
Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Huma | 1998 |
New combinations with Herceptin in metastatic breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormo | 2001 |
Chemotherapy of prostatic cancer.
Topics: Aged; Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic Agents; Bromoc | 1975 |
88 trials available for fluorouracil and Blood Diseases
| Article | Year |
|---|---|
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2018 |
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pa | 2018 |
Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2019 |
Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Blood Platelets; Capecitabine; Dacarbazine; Deoxycytidin | 2014 |
Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2014 |
Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Pr | 2008 |
Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedul | 2008 |
Glutathione S-transferase P1 Ile105Val polymorphism is associated with haematological toxicity in elderly rectal cancer patients receiving preoperative chemoradiotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; | 2008 |
Role of low dose capecitabine combined to irinotecan in advanced and metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2010 |
[Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2011 |
Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Disease-Free Survival | 2011 |
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2013 |
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2013 |
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2013 |
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2013 |
Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2002 |
A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2002 |
Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2002 |
[Hungarian experience with docetaxel combination (TAC) in the adjuvant treatment of breast cancer. Results of BCIRG 001 randomized, multicentric, phase III trial].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2003 |
A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Fatigu | 2004 |
Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; | 2004 |
Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemother | 2004 |
Gemcitabine combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced carcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2004 |
Phase II study of irinotecan (CPT-11) administered every 2 weeks as treatment for patients with colorectal cancer resistant to previous treatment with 5-fluorouracil-based therapies: comparison of two different dose schedules (250 and 200 mg/m2) according
Topics: Adult; Aged; Camptothecin; Colorectal Neoplasms; Confidence Intervals; Drug Administration Schedule; | 2004 |
A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2005 |
Phase one dose finding study of capecitabine (Xeloda), radiotherapy and cisplatin in the treatment of locally advanced squamous cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; | 2005 |
Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2005 |
Quality-of-life assessment after hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in inoperable and/or unresectable head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2005 |
Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deox | 2005 |
Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony sti
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemother | 2006 |
Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2006 |
Mitomycin C, 5-fluorouracil, leucovorin, and oxaliplatin as a salvage therapy for patients with cisplatin-resistant advanced gastric cancer: a phase I dose escalation trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose- | 2007 |
A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2008 |
Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2007 |
A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2008 |
Postoperative chemoradiotherapy in gastric cancer -- a Phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2007 |
A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; F | 2007 |
A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineop | 2008 |
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carci | 2008 |
Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial.
Topics: Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2008 |
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Ne | 2008 |
Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2008 |
Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineo | 2007 |
Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuva | 2008 |
Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2008 |
Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Biomark | 2008 |
Efficacy of MER immunotherapy when added to a regimen of 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel. A Veterans Administration Surgical Oncology Group report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Clinical Trials as Topic; | 1984 |
Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. A Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Therapy, | 1983 |
Methotrexate and 5-fluorouracil in sequence in squamous head and neck cancer.
Topics: Carcinoma, Squamous Cell; Clinical Trials as Topic; Drug Administration Schedule; Drug Synergism; Dr | 1983 |
Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cycloph | 1983 |
Efficacy of prolonged intermittent therapy with combined 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel. A Veterans Administration Surgical Oncology Group report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi | 1984 |
Chemotherapy of advanced colorectal carcinoma: fluorouracil alone vs. two drug combinations using fluorouracil, hydroxyurea, semustine, dacarbazine, razoxane, and mitomycin. A phase III trial by the Eastern Cooperative Oncology Group (EST: 1278).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Ne | 1984 |
Drug combinations in the treatment of gastric adenocarcinoma: a randomized Southwest Oncology Group study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Sch | 1984 |
The activity of paclitaxel in gastrointestinal tumors.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 1995 |
Dose-escalating induction chemotherapy supported by lenograstim preceding high-dose consolidation chemotherapy for advanced breast cancer. Selection of the most acceptable regimen to induce maximal tumor response and investigation of the optimal time to c
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubic | 1994 |
A pilot study of accelerated cyclophosphamide, epirubicin and 5-fluorouracil plus granulocyte colony stimulating factor as adjuvant therapy in early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1994 |
Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 1995 |
A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1995 |
5-Fluorouracil-interferon-alpha 2b adjuvant treatment of Dukes C colorectal cancer.
Topics: Aged; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Colonic Neoplasms; Confidence | 1994 |
Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemo | 1993 |
Pilot study of 6 weeks of chemoradiotherapy with 5 FU and hydroxyurea in malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined | 1993 |
Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1993 |
Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collab
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemother | 1996 |
Pilot study of ambulatory infusional delivery of a multidrug regimen: cisplatin, 5-fluorouracil and leucovorin (PFL) +/- etoposide.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Car | 1996 |
A phase II trial of etoposide, leucovorin and 5-fluorouracil (ELF) in patients with advanced gastric cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouracil; Hematologic | 1996 |
Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients. Scandinavian Breast Group, Study SBG 9401.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cycl | 1998 |
Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group.
Topics: Adult; Age Factors; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neop | 1998 |
Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Color | 1999 |
Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asbestos; Cisplatin; Combined Modality | 1999 |
Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Surv | 1999 |
Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies.
Topics: Acetates; Adult; Antimetabolites, Antineoplastic; Cytoprotection; Diarrhea; Dose-Response Relationsh | 2000 |
Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2000 |
Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study (PB586).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogen | 2000 |
Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients.
Topics: Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco | 2000 |
Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Bilia | 2001 |
[Cisplatin and vinorelbine therapy of previously treated advanced breast cancer (preliminary studies)].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide | 2001 |
A Swedish study of chemoradiation in squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2001 |
Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla | 2001 |
Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2002 |
Trimetrexate in untreated and previously treated patients with metastatic breast cancer: a Cancer and Leukemia Group B study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; | 1991 |
Continuous infusion 5-fluorouracil with escalating doses of intermittent cisplatin and etoposide. A phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Dose-Respo | 1991 |
A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neopla | 1991 |
Association of bolus tetrahydropyranyl adriamycin and 120 hours continuous 5-fluorouracil infusion in patients with metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 1990 |
A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Costs and | 1985 |
Phase III study of 5-FU and carmustine versus 5-FU, carmustine, and doxorubicin in advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Doxorubicin; F | 1986 |
Randomized comparison of 5-FU alone or combined with carmustine, doxorubicin, and mitomycin (BAFMi) in the treatment of advanced gastric cancer: a phase III trial of the Italian Clinical Research Oncology Group (GOIRC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; D | 1986 |
The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 1985 |
Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined | 1985 |
Prospective randomized trial of intravenous v intraperitoneal 5-FU in patients with advanced primary colon or rectal cancer.
Topics: Adult; Catheters, Indwelling; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Colo | 1985 |
64 other studies available for fluorouracil and Blood Diseases
| Article | Year |
|---|---|
Haematotoxicity in IMRT/VMAT curatively treated anal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, | 2020 |
Toxicity profile of taxanes in Tunisian cancer patients: A retrospective study of 90 cases.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Digestive System Diseases | 2021 |
Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophagogastric Junction; Female; F | 2022 |
The Prognostic Nutrition Index Predicts the Development of Hematological Toxicities in and the Prognosis of Esophageal Cancer Patients Treated with Cisplatin Plus 5-Fluorouracil Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C | 2018 |
Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Capecitabine; Chemoradioth | 2018 |
Safety and efficacy of modified FOLFOX6 plus high-dose bevacizumab in second-line or later treatment of patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
Toxicity of oxaliplatin plus fluorouracil/leucovorin adjuvant chemotherapy in elderly patients with stage III colon cancer: a population-based study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colonic Neopla | 2014 |
O-MAX chemotherapy: high activity in metastatic esophagogastric adenocarcinoma and possible relation to subclinical hemolysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2014 |
Clinical and dosimetric predictors of acute hematologic toxicity in rectal cancer patients undergoing chemoradiotherapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemoth | 2014 |
Concurrent radiotherapy and weekly chemotherapy of 5-fluorouracil and platinum agents for postoperative locoregional recurrence of oesophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Drug Administration | 2015 |
Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chem | 2015 |
Antitoxic Activity of Extract from Salix Viminalis Leaves under Conditions of 5-Fluorouracil Treatment.
Topics: Animals; Antimetabolites, Antineoplastic; Blood Cell Count; Bone Marrow; Carcinoma, Lewis Lung; Cyto | 2015 |
Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus | 2017 |
FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Cam | 2016 |
Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asth | 2016 |
Lumbar-sacral bone marrow dose modeling for acute hematological toxicity in anal cancer patients treated with concurrent chemo-radiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bone Marrow; Chemoradio | 2016 |
Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; A | 2009 |
Lack of large intragenic rearrangements in dihydropyrimidine dehydrogenase (DPYD) gene in fluoropyrimidine-treated patients with high-grade toxicity.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Exons; Female; Flu | 2009 |
The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2010 |
Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squam | 2012 |
Adjuvant chemotherapy and risk of gastrointestinal, hematologic, and cardiac toxicities in elderly patients with stage III colon cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; | 2012 |
Final results of an international retrospective observational study in patients with advanced breast cancer treated with oral vinorelbine-based chemotherapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineo | 2012 |
Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 2013 |
[Chemoradiotherapy in locally advanced cancers of the uterine neck. Retrospective study of 92 patients treated at the Institute Curie between 1986 and 1998]].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2002 |
Capecitabine named-patient programme for patients with advanced breast cancer. the UK experience.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deo | 2002 |
Concurrent chemoradiotherapy with low-dose cisplatin plus 5-fluorouracil for the treatment of patients with unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2002 |
Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen).
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2003 |
Concurrent sequencing of full-dose CMF chemotherapy and radiation therapy in early breast cancer has no effect on treatment delivery.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 2003 |
Protective effects of glutathione on 5-fluorouracil-induced myelosuppression in mice.
Topics: Administration, Oral; Animals; Body Weight; Bone Marrow; Drug Antagonism; Female; Fluorouracil; Glut | 2003 |
[Prognostication of hematotoxicity for radio- and chemotherapy in patients with breast cancer].
Topics: Adult; Aged; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Ne | 2003 |
Neoadjuvant chemotherapy with cyclophosphamide, mitoxantrone, and 5-fluorouracil in locally advanced breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brea | 2005 |
Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cycl | 2005 |
Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols | 2005 |
Increased dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil and leucovorin.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast | 2007 |
The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capecitab | 2008 |
A retrospective study of definitive chemoradiotherapy for elderly patients with esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cisplatin; Combined Modality T | 2007 |
5-Fluorouracil and folinic acid: a Phase I-II trial in gastrointestinal malignancy.
Topics: Adenocarcinoma; Adult; Aged; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Ga | 1984 |
Allopurinol modulation of fluorouracil toxicity.
Topics: Allopurinol; Drug Eruptions; Drug Therapy, Combination; Fluorouracil; Hematologic Diseases; Humans; | 1981 |
Sequential methotrexate and 5-FU in CMFP (cyclophosphamide, methotrexate, 5-FU, and prednisone) therapy for breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclo | 1984 |
High-dose cyclophosphamide and high-dose 5-fluorouracil. A new first-line regimen for advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 1984 |
Enteral versus parenteral nutritional support in cancer patients.
Topics: Animals; Cachexia; Enteral Nutrition; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; | 1981 |
Pathology induced by interleukin-6.
Topics: Acute-Phase Reaction; Animals; Female; Fluorouracil; Hematologic Diseases; Hematopoiesis; Humans; Im | 1993 |
Sequence-dependent antitumour efficacy of combination chemotherapy of nedaplatin, a novel platinum complex, with 5-fluorouracil in an in vivo murine tumour model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Dose-Response Relati | 1998 |
Concurrent chemotherapy and radiotherapy in invasive cervical cancer patients with high risk factors.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 2000 |
A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2001 |
Dose intensity of chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil in the elderly with advanced breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 1992 |
A pilot study of three sequential chemotherapeutic regimens in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1991 |
Adjuvant therapy of stage II breast cancer treated with CMFVP, radiation therapy and VATH following lumpectomy. A pilot trial.
Topics: Adjuvants, Pharmaceutic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 1991 |
Pirarubicin in combination chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1990 |
Phase I study of a 120-hour continuous intravenous infusion of 5-fluorouracil in pediatric patients with recurrent solid tumors: a Pediatric Oncology Group study.
Topics: Adolescent; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Child; Dose-Res | 1990 |
The effect of sequential methotrexate and 5-fluorouracil in patients with recurrent head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Drug Administration Schedule | 1989 |
5-Fluorouracil rechallenge by protracted infusion in refractory breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Fluorouracil; Hematologic Diseases; Humans; Infusions, Intravenous; M | 1989 |
Schedule-dependency of in vivo modulation of 5-fluorouracil by leucovorin and uridine in murine colon carcinoma.
Topics: Animals; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combinat | 1989 |
High-dose folinic acid and 5-fluorouracil in advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Gastr | 1988 |
A phase I-II trial of carboplatin and 5-fluorouracil combination chemotherapy in advanced carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1987 |
Combination chemotherapy and systemic irradiation consolidation for poor prognosis breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Combi | 1987 |
Failure of allopurinol to provide clinically significant protection against the hematologic toxicity of a bolus 5-FU schedule.
Topics: Adenocarcinoma; Adult; Allopurinol; Carcinoma, Squamous Cell; Colonic Neoplasms; Drug Administration | 1986 |
Chemoradiotherapy as initial management in patients with squamous cell carcinoma of the head and neck.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1986 |
Weekly 5-fluorouracil combined with PALA: toxic and therapeutic effects in colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Central Nervous System D | 1987 |
Phase I-II trial with cisplatin and 5-FU in recurrent head and neck cancer: an effective outpatient schedule.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Ce | 1985 |
Cisplatin plus 5-FU for the treatment of adenocarcinoma of the colon.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antige | 1985 |
Palliative treatment of metastasized breast cancer with 5-FU in slow intravenous infusion.
Topics: Adult; Breast Neoplasms; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Huma | 1969 |
Therapy of advanced gastrointestinal cancer with the nitrosoureas.
Topics: Adenocarcinoma; Antineoplastic Agents; Bone Marrow Diseases; Carmustine; Colonic Neoplasms; Cyclohex | 1973 |
[Hematopoietic changes following use of fluorouracil in animals with toxic hepatitis].
Topics: Anemia, Aplastic; Animals; Carbon Tetrachloride Poisoning; Chemical and Drug Induced Liver Injury; F | 1970 |